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CHAPTER 1 INTRODUCTION 
1.1. Endothelial Progenitor Cell Discovery 
The process of postnatal formation of blood vessels was traditionally 
believed to result from proliferation of pre-existing mature endothelial cells, which 
is termed angiogenesis[1]. Thanks to Asahara and coworkers’ isolation of 
endothelial progenitor cells (EPCs) from human peripheral blood, our 
understanding to the mechanism responsible for new blood vessel formation was 
extended [2]. Their discovery of EPCs has introduced the concept of 
vasculogenesis [2]. After that, postnatal vasculogenesis was defined as the 
process that progenitor differentiate into mature endothelial cells and promote 
postnatal new blood vessel formation [2, 3].  
Since the discovery of EPCs by Asahara’s group, a substantial amount of 
investigations showed that bone marrow-derived EPCs contribute to new blood 
vessel formation by promoting the function of endothelium, incorporating into sites 
of active neovascularization such as ischemic hind limbs, myocardium infarction, 
and progressing tumors [4-7]. Recently, EPCs has been reported to be an 
independent risk factor of cardiovascular diseases [8]. It is also reported that EPCs 
are decreased in artery disease [9-11] but elevated in several types of cancer [12]. 
These studies have highlighted the potential importance of EPCs in 
neovascularization or angiogenesis related diseases [13]. Understanding of EPC 
biology provides us a better chance to manipulate EPCs and treat blood vessel 
formation related diseases. EPCs can be easily obtained from bone marrow, 
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peripheral blood, and spleen, and they can be expanded or manipulated in vitro 
before transplantation. 
1.2. Classification of Endothelial Progenitor Cells. 
In the bone marrow, EPCs are derived from mesodermal cells which 
ultimately differentiate into endothelial cells [14, 15]. Since the discovery of EPCs 
in 1997, different groups have tried to define and characterize this population. 
However, despite those efforts and the increasing number of publications in EPC 
biology, no exclusive definition of EPCs has been identified. So the EPC is 
considered to be a group of cells that are derived from bone marrow, are able to 
proliferate, and are able to differentiate from progenitor phenotype to mature 
endothelial phenotype.  
Different cell surface molecules have been mainly utilized to characterize 
and define EPCs. Initially, three markers were used to characterize the early EPC: 
CD133, CD34, and vascular endothelial growth factor receptor-2 (VEGFR2) which 
is also known as Flk-1 or kinase insert domain (KDR) [16, 17]. EPCs from 
peripheral blood express CD34 and VEGFR2 but no longer express CD133. 
Endothelial cells are also negative for CD133 [18]. So loss of CD133 expression 
is accompanied with EPC maturation. 
During almost two decades of study, a variety of approaches to isolate 
EPCs were developed, such as flow cytometry to analyze EPC markers [2, 19] and 
several type of colony forming assays [8, 20-23]. These studies have indicated that 
EPC is a type of heterogeneous cell population rather than a single type of cell 
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population. Figure 1.1 showed the putative cascade of bone-marrow derived EPC 
differentiation. 
 
 
          
 
 
Figure 1.1 Putative origin and differentiation cascade of EPCs. 
Schematic diagram shows the potential differentiation cascade of EPC from 
hemangioblast cells. Figure is from [24]. Dash arrow line: Some isolated EPCs 
possess endothelial-like cell surface marker but function as monocytes, indicating 
the putative origin of that portion of EPCs is monocyte but lack of direct evidence. 
 
 
4 
 
 
  
Although different nomenclatures have been used in attempting to 
distinguish EPCs from other progenitor cells with angiogenic activities according 
to their morphology, expression of cell surface markers, and cellular phenotype, 
there is still no precise description to define them. One of the general 
classifications of EPCs is based on the time they have been cultured in vitro, 
according to which EPCs are divided into early and late EPC [25]. Generally, bone 
marrow or peripheral derived mononuclear cells differentiated EPCs start to 
emerge in fibronectin coated plated containing endothelial growth media within a 
week, which is considered to be early EPCs. These cells have low proliferation 
potential, display spindle shaped morphology and express VEGFR2 and VE-
cadherin, CD14 and CD45 [7, 26, 27]. These early EPCs can be cultured for 4 
weeks, while continued culturing resulted in morphological and phenotypical 
changes in the cells, such as loss of hematopoietic marker and gain of endothelial 
marker [26]. Late EPCs started to emerge after 2-3 weeks in cell culture. Different 
from early EPCs, late EPCs are more proliferative, and they incorporate into 
endothelial monolayer more rapidly [25]. 
A variety of studies have reported the functional significance of early and 
late EPCs. Early EPCs are reported to homing and incorporate into ischemic loci 
to promote new blood vessel formation mainly by secreting angiogenic factors [7, 
18, 28-31].  Late EPCs is reported to promote revascularization in a synergistic 
manner with early EPCs [32]. Similar to early EPCs, in vivo studies have 
demonstrated that administration of late EPCs into ischemic mice also resulted in 
enhanced angiogenesis [7, 15, 33, 34]. Moreover, detailed studies indicated that 
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late EPCs participate in the process of blood vessel formation by directly 
incorporating into endothelial network and provide building blocks for 
neovascularization [4, 35, 36]. 
1.3. EPC mobilization and homing 
EPCs reside in the stem cell niche of bone marrow which also contains 
fibroblasts and osteoblasts. Certain cytokines secreted from local 
microenvironments interrupt the interaction between EPCs and bone marrow 
stromal cells and improve the EPC transendothelial migration to promote the EPC 
entering the circulation system. A variety of chemokines and growth factors have 
been reported to contribute to EPC mobilization. Stromal derived factor 1 (SDF-1) 
has been documented to play critical roles in EPC mobilization, especially in the 
situation of ischemia. It is reported that disruption of SDF-1 mediated interaction 
between EPC and bone marrow stromal cells and elevation of circulating SDF-1 
are important for EPC mobilization. Moreover, it is believed that SDF-1 mobilize 
EPCs in a matrix metalloproteinase 9 (MMP-9) dependent manner [37]. The SDF-
1/CXCR4 signaling pathway has been reported to play important roles in EPC 
biology [38, 39]. 
Vascular endothelial growth factor (VEGF) has also been reported to 
contribute to EPC mobilization through promoting EPC proliferation and increasing 
the expression of MMP-9 [40]. Erythropoietin (EPO), colony stimulating factor (G-
CSF) and granulocyte monocyte colony stimulating factor (GM-CSF) are also 
reported to be able to increase circulating EPC amount by stimulating EPC 
proliferation [41-44]. Moreover, in vitro and in vivo studies have demonstrated that 
6 
 
 
  
CXCL5 and CXCL8, which have been considered as pro-inflammatory 
chemokines at the beginning, also play important roles in EPC mobilization [45].  
 Mediated mainly by chemokine/chemokine receptor axis, EPCs will home 
to the sites of ischemia or vascular injury to participate in blood vessel formation 
either directly or indirectly. Accumulating evidence have shown that several 
chemokine/chemokine receptor pairs play major roles in regulating EPC homing. 
Monocyte chemoattractant protein-1 (MCP-1), which is one of the CCR2 ligands, 
is present in the sites of endothelial denudation [46]. It is also reported that MCP-
1/CCR2 axis is essential for directing EPCs into tumor neovessels [47]. Moreover, 
it is well documented that SDF-1/CXCR4 axis acts as a key element for EPC 
recruitment towards hypoxic gradient and arterial injury sites [48, 49].  
Recently, the in vivo studies have revealed the importance of CXCR2, a 
CXC chemokine receptor which was initially identified in leukocyte recruitment [50], 
in EPC recruitment [51]. In the study, CXCL1 and CXCL7, which are both CXCR2 
ligands, were able to arrest flowing EPCs, and blockade of CXCR2 attenuated the 
recruitment of EPCs [51, 52]. Furthermore, it has also been reported that CXCL12 
and CXCL7 mediated the homing of EPC at early stage after arterial injury and 
later stage of which was mediated by CXCL1 [53]. 
1.4. Paracrine action of EPC 
During the process of investigating EPC biology, some groups have noticed 
that the observed beneficial effects were not proportional to the amount of 
incorporated EPCs, indicating certain unidentified roles that EPCs have played 
during those processes. Growing evidence indicates that EPCs participate in 
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maintaining the integrity of vascular structure by improving blood vessel formation 
through both secreting proangiogenic factors and incorporating into endothelial 
network to differentiate into mature endothelial cells. Reports from multiple groups 
have supported this notion that EPC is an important source of chemokines and 
growth factors. It is believed that EPCs release factors that promote the functions 
of resident mature endothelial cells [18, 54]. Recently, it is reported that under 
hypoxic condition EPCs secret several kinds of chemokines and growth factors 
including CXCL1, SDF-1, VEGF, and macrophage migration inhibitory factor (MIF), 
which promoted the EPC adhesion, migration, and transmigration through 
endothelial layers [55]. In agreement with this finding, another group has also 
detected several chemokines, such as growth-regulated protein-α (GROα), CXCL-
8, EGF, and MCP-1, in EPC conditioned medium. Furthermore, the authors also 
found that the EPC-conditioned medium promoted endothelial cell viability, cell 
migration, and angiogenesis through phosphoinositide 3-kinase/protein kinase B 
(PI3K/Akt) and mitogen-activated protein kinase-kinase/ extracellular signal-
regulating kinase (MEK/ERK) pathways [56]. Moreover, the paracrine factors 
secreted by EPCs were also able to protect endothelial cells from apoptosis and 
promote their angiogenic potency [57]. These secreted factors not only exert their 
activities on endothelial cells but also promote the EPCs’ function, such as 
incorporating into growing capillaries [25].  
Based on the previous findings, it is clear that EPCs need to undergo 
multiple steps in order to contribute to the regeneration of blood vessel as shown 
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in Figure 1.2. Dysregulation of any step during this process will prevent EPCs 
performing normal functions, which can be observed in diseases. 
 
 
 
Figure 1.2 EPCs contribute to blood vessel regeneration.  
EPCs need to undergo multiple steps including mobilization, chemotaxis, invasion, 
migration, differentiation, as well as pro-angiogenic factor secretion to contribute 
to the blood vessel formation. (Figure adopted from [15]) 
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1.5. EPCs and diseases 
The first report describing the contribution of EPC to tumor related 
vasculogenesis was in 2001 [58]. Lyden et al. demonstrated that bone marrow 
from wild-type mice, rather than that from angiogenesis-defective Id-mutant mice, 
restored tumor angiogenesis and growth [58]. The contribution of EPCs to tumor 
blood vessel formation varies among different studies. Meanwhile, clinical study 
has also been carried out in patients suffered from cancer after bone marrow 
transplantation. The contribution of bone marrow derived EPCs to tumor 
angiogenesis varies from 1% to 12.1% [59]. On the other hand, EPCs also 
contribute to the tumor vascularization indirectly through their paracrine activity. It 
has been reported that blocking EPC mobilization has significantly reduced the 
tumor angiogenesis and progression [60]. Other groups also demonstrate that 
EPCs promote angiogenesis by releasing pro-angiogenic factors, such as VEGF 
and SDF-1 [61, 62]. Because of their contribution to tumor related vascularization, 
EPCs have been considered to be a potential biomarker in various clinical studies 
as shown in Table 1.1 (Reviewed in [63]). In summary, accumulating evidence 
indicates that EPCs contribute to tumor related blood vessel formation directly and 
indirectly, and consequently, they have been considered as a potential tumor 
biomarker.  
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Table 1.1 Studies evaluating circulating EPCs levels compared to healthy controls 
in cancer patients. Modified from [63] 
Author/Year Cancer types EPC definition Circulating 
EPC levels 
P value 
Ho/2006 Hepatocellular 
Carcinoma 
CD34+ CD133+ 
VEGFR2+ 
Increased <0.01 
Dome/2006 Non-Small Cell Lung 
Cancer 
CD34+ VEGFR2+ Increased <0.002 
Zheng/2007 Glioma CD34+ CD133+ 
VEGFR2+ 
increased <0.001 
Yu/2007 Hepatocellular 
Carcinoma 
CD34+ CD133+ Increased <0.01 
Richter-
Ehrenstein/2007 
Breast Cancer CD34+ VEGFR2+ Increased <0.001 
Brunner/2008 Head and Neck Cancer CD133+ VEGFR2+ Increased <0.001 
Bogos/2009 Small Cell Lung Cancer CD34+ VEGFR3+ Increased <0.01 
Sieghart/2009 Hepatocellular 
Carcinoma 
CD34+ CD133+ 
VEGFR2+ 
Increased <0.01 
Goon/2009 Breast Cancer CD34+ VEGFR2+ Increased <0.05 
Rafat/2010 Glioma CD34+ VEGFR2+ Increased <0.05 
Nowak/2010 Lung Cancer CD34+ CD133+ 
VEGFR2+ 
Increased <0.001 
Su/2010 Ovarian Cancer  CD34+ VEGFR2+ Increased  <0.01 
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Table 1.1 Continued 
Author/Year Cancer types EPC definition Circulating 
EPC levels 
P value 
Bhatt/2011 Renal Cell 
Carcinoma 
CD34+ CD133+ 
CD146+ CD45- 
Increased <0.01 
Bhaskar/2012 Multiple 
Myeloma 
CD31+ CD34+ 
CD133+ CD45- 
Increased <0.001 
Yang/2012 Renal Cell 
Carcinoma 
CD34+ VEGFR2+ 
CD45- 
Increased <0.001 
Qiu/2013 Ovarian 
Cancer 
CD34+ VEGFR3+ Increased <0.01 
Ha/2013 Gastric Cancer CD34+ CD133+ Increased <0.05 
Ramcharan/2013 Colorectal 
Cancer 
CD34+ VEGFR2+ 
CD45- 
Increased <0.001 
Kim/2014 Ovarian 
Cancer 
CD31+ CD133+ 
VEGFR2+ CD45- 
Increased <0.05 
Kim/2014 Cervical 
Cancer 
CD31+ CD133+ 
VEGFR2+ CD45- 
Increased <0.01 
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Moreover, increasing body of evidence has demonstrated the correlation 
between the amount and function of EPCs and the cardiovascular disease risk 
factors which includes diabetes, hypertension, aging, smoking, and 
hypercholesterolemia.  
Diabetes is a critical cardiovascular risk factor and it is negatively 
associated with circulating EPC number and function. EPC dysfunction is a major 
problem in diabetes related cardiovascular symptoms and vascular complications 
[10, 64-66]. Under the diabetic conditions, the number of circulating EPCs are 
decreased. In both type 1 and type 2 diabetic patients, the amount of circulating 
EPCs are decreased compared to the healthy control subjects [10, 66-68]. Along 
with the decrease in the EPC counts, findings from clinical studies indicate that the 
EPC functions, such as proliferation, adhesion, and incorporation, are also 
impaired under the conditions of diabetes [10, 64, 69-71]. These impairment in 
EPC functions may be due to their decreased response to stimuli [72, 73] and 
dysfunction in paracrine abilities [10]. 
The EPC counts and functions are also negatively related to aging, which 
is an important cardiovascular disease risk factor. It has been reported that EPCs 
from younger mice restored the impaired blood vessel formation in older mice [74]. 
In clinical studies, decreased circulating EPC number with aging in patients with 
coronary artery disease have also been described by several groups [9, 75]. It has 
been proposed that the aging related EPC dysfunction may result from reduced 
levels of pro-angiogenic factors, enhanced senescence, and accelerated 
apoptosis [8, 76-78].  
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Lipid metabolism such as hypercholesterolemia has also been related to 
circulating EPC number and function. It has been reported that EPCs from patients 
with hypercholesterolemia display impaired proliferation, migration and adhesion 
activities [79, 80]. Meanwhile, increasing evidence has demonstrated the 
association between EPC number and function with other cardiovascular disease 
risk factors such as smoking and hypertension [9].  
It is considered that mobilized EPCs migrate to the injured vascular, such 
as ischemic tissue or infarcted cardiomyocyte, to promote vascularization and 
tissue repair [7, 81-83].  Many pre-clinical investigations have confirmed the 
therapeutic potential of EPCs by using animal models with myocardial infarction 
and hind limb ischemia [54, 84]. In the clinical studies, EPCs also displayed their 
therapeutic capacities. A large number of pre-clinical studies have shown that 
patients with cardiovascular disease and severe leg ischemia benefited from EPC 
administration as shown in table 1.2. (Reviewed in [69]) 
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Table 1.2 Therapeutic effect of EPC therapy 
Author Disease n Method of delivery Effects 
Perin Severe 
ischemic 
heart failure 
21 Intramyocardial injection Myocardial perfusion↑; EF↑; 
ESV↓ 
Strauer Acute MI 10 Intracoronary infusion Infarct area↓, ESV↓;  
Myocardial viability↑; SV↑ 
Assmus Acute MI 40 Intracoronary infusion EF↑; Local contractility↑ 
Myocardial viability↑ 
Coronary flow reserve↑; ESV↓ 
Wollert Acute MI 30 Intracoronary infusion EF↑ 
Fernandez-
Aviles 
Acute MI 20 Intracoronary infusion EF↑; Local contractility↑; ESV↓ 
Hamano CABG 5 Injection in myocardial CABG Myocardial perfusion↑ 
Tateishi-
Yuyama 
Severe leg 
ischemia 
25 Injection into the gastrocnemius 
muscle 
ABI↑; physical tolerance↑; 
tissue perfusion↑; Rrest pain↓ 
 
Therapeutic of injection based EPC therapy in different diseases. CABG, coronary 
artery bypass graft; MI, myocardial infarction; EF, ejection fraction; ESV, end 
systolic volume; SV, stroke volume; LV, left ventricle; ABI, ankle-brachial index. 
(Table is adopted from Shantsila et al [69]) 
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1.6. GPCR overview 
G protein-coupled receptor, which is also known as seven transmembrane 
receptor, is a superfamily of integral membrane proteins containing one 
extracellular N-terminus, three intracellular loops, three extracellular loops, and 
one intracellular C-terminus [85]. GPCRs contain one of the largest and most 
investigated population of proteins in mammalian genomes [86]. GPCRs can be 
detected in all types of tissues and they participate in a variety of cellular activities. 
GPCRs transduce extracellular signals into the cells and regulate cellular activities 
through their bound G proteins [85, 87, 88]. G proteins, also known as guanine 
nucleotide-binding proteins, are composed of three non-identical subunits which 
are α, β, and γ subunits [89]. Each subunit contains several isoforms, which makes 
a variety of combinations of G proteins, resulting in the complex network of 
signaling transduction [89, 90]. G protein is reported to be associated with the third 
intracellular loop of the GPCRs, and binding of ligands to GPCRs results in their 
conformational change and, consequently, release of the heterotrimeric G proteins 
which further activate downstream signaling molecules, such as phospholipase C 
beta (PLC-β) and adenylyl cyclase (AC) [89, 91-93] (as shown in Table 1.3). 
Unregulated GPCRs have been reported in a variety of pathological conditions 
including cancer development and progression [94-96]. Accordingly, GPCR are 
also considered as a potential therapeutic target by pharmaceutical companies, 
and nearly 40% of modern drugs target GPCRs [97]. Moreover, those drugs have 
only targeted a small portion of identified GPCRs. On the other hand, there are still 
large amount of GPCRs, whose functions and ligands are still not clear, have been 
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termed as orphan receptors [98-100]. Further studying GPCRs will improve our 
understanding of this group of proteins and eventually improve the development 
of disease therapies.  
 
Table 1.3. G-protein subunits and their functions. (modified from [89]) 
G-protein Effector Effect 
α-subunit   
Gαi1  Gαi2   Gαi3  GαoAB  Gαz Adenylyl cyclase Inhibition 
Gαt1  Gαt2  Gαgust Phosphodiesterase Activation 
Gαs   GαsXL  Gαolf Adenylyl cyclase Stimulate 
Gαq  Gα11 Gα14-16 Phospholipase Cβ Stimulate 
Gα12  Gα13 Rho guanine nucleotide-exchange factors Stimulate 
Gβγ-subunit 
Phospholipase A, Phospholipase Cβ1-3, 
Adenylyl cyclase (type II, IV),  
Activation 
N-type calcium channel, P/Q-type calcium 
channel, Adenylyl cyclase (type I, III, V, VI, 
VII), PI3K, p21-activated protein kinase 
Inhibition 
1.7. GPCR signaling 
G proteins are composed of three non-identical subunits [89]. G proteins 
usually exist in the heterotrimeric form containing α, β, and γ subunit [101, 102]. It 
is reported that α subunit contains 17 isoforms, the β subunit contains 5 isoforms, 
and γ subunit has 12 isoforms [89, 90]. When bound to GDP, the α subunit forms 
the complex with βγ heterodimer and associate with GPCRs, and when the α 
subunit binds GTP, it functionally dissociates from the βγ complex and regulates 
the downstream signaling effectors [91]. Generally, G proteins are termed 
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according to α subunit, which give rise to the Gs (contains Gαs); Gq (includes Gαq); 
Gi (includes Gαi); and so on. Gs couples to a large number of GPCRs and activates 
AC, which is responsible for the synthesis of the second messenger, cyclic AMP 
(cAMP). On the other hand, Gi inhibits the cAMP synthesis by inhibiting the activity 
of adenylyl cyclase. Gq is reported to stimulate PLC-β, and Gα12 activates the 
activities of Rho-Guanine Nucleotide Exchange Factors (GEFs) [89, 103]. 
Meanwhile, β and γ subunits function in the form of heterodimer are also capable 
of transducing signaling toward its own downstream effectors, such as PLC-β, AC, 
and K+ channels [104-108] (as shown in table 1.3). Moreover, G proteins have also 
been reported to activate p38 mitogen-activated protein kinase (p38MAPK), 
extracellular signaling-related protein kinase (ERK1/2), and c-Jun N-terminal 
kinase (JNK) pathways [109-112].  
1.8. Chemokine and CXCR2 
Chemokines are a subtype of chemotactic cytokines, which were identified 
as cytokines that activated neutrophils [113]. They exert their activities to regulate 
cellular functions through GPCRs [114-116]. Based on the spacing of the first two 
cysteines at the N-terminus, chemokines have been divided into four subgroups: 
C, CC, CXC, and CX3C chemokines, in which X represents any non-cysteine 
amino acids [117-119] as shown in Figure 1.3. Within the chemokine sub-families, 
CXC chemokines are further classified into two categories based on the presence 
of a specific short peptide sequence: glutamic acid-leucine-arginine (ELR) at the 
N-terminus. Accordingly, CXC chemokine are subclassified into ELR+ and ELR- 
CXC chemokines [120]. ELR+ CXC chemokines include: interleukin-8 (IL-
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8/CXCL8), epithelial neutrophil activating protein-78 (ENA-78/CXCL5), 
granulocyte chemotactic peptide-2 (GCP-2/CXCL6), neutrophilic activating protein 
(NAP-2/CXCL7), melanoma growth stimulatory activities (GROα,β,γ/CXCL1-3) 
[117]. It has been well accepted that ELR+ CXC chemokines are actively involved 
in angiogenesis [121, 122], recruitment of stromal cells to tumor microenvironment, 
and cancer progression [96]. By contrast, ELR- CXC chemokines, platelet factor-
4 (PF-4) has been shown to have angiostatic properties [120]. Since Murphy et al 
identified the CXCR1 and CXCR2 in neutrophils in 1991, more and more 
chemokine receptors have been identified [123]. These chemokine receptors 
share several common properties. All of them are integral membrane proteins 
containing one extracellular N-terminus, three intracellular loops, three 
extracellular loops, and one intracellular C-terminus [85]. These chemokine 
receptors can be modified through glycosylation at their N-terminus, and their 
activities can be regulated by serine and threonine phosphorylation at their 
intracellular C-terminus. Moreover, the cysteines located at the first and second 
extracellular loops usually form a disulfide [124]. Generally, many chemokines 
have more than one receptors and many chemokine receptors have multiple 
ligands [117]. For example, ELR+ chemokine IL-8 stimulates both CXCR1 and 
CXCR2, which are highly homologous [123, 125]. CXCR1 binds to IL-8 or CXCL6, 
however, CXCR2 is able to interact with CXCL1, 2, 3, 5, 6, 7 and 8 [116].  
CXCR2 is widely expressed in a variety of cell types including neutrophils 
[50], epithelial cells [96], smooth muscle cells, monocytes, and endothelial 
progenitor cells [45]. It has been reported to be involved in multiple cellular 
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activities such as cell proliferation, migration, angiogenesis, as well as survival [50, 
96]. Activated by its ligands, G protein dissociates from CXCR2 and activate 
different downstream effectors such as cAMP/PKA, PKC, PLC, PI3K/AKT, 
Ras/Raf/MAPK, and even NF-κB pathways to regulate different cell functions [126-
129]. 
 
 
 
 
 
                
Figure 1.3. Classification of chemokine. 
Based on the spacing of the first two cysteines at the N-terminus, chemokines have 
been divided into four subgroups: C, CC, CXC, and CX3C chemokines, in which 
X represents any non-cysteine amino acids. CX3C chemokines possess additional 
mucin-like domain and cytoplasmic domain. (Figure from [130]) 
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1.9. PDZ domain, PDZ motif and PDZ mediated protein-protein interaction 
PDZ domain, the name of which comes from the first three proteins 
observed containing this domain: post synaptic density protein 95 (PSD-95), 
Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein 
(ZO-1), mediates protein-protein interactions by recognizing and physically 
interacting with short binding motifs which usually is located at the carboxyl termini 
of proteins [131, 132]. Previous studies from our lab and others’ have 
demonstrated that PDZ domain mediated protein-protein complexes play 
important roles in facilitating signaling transduction in different types of cells [50, 
96, 133]. Composed of one β strand and one α helices, the binding groove of PDZ 
domain specifically recognize and bind the short binding motif, which is usually 4 
~ 5 residues in length, referred as PDZ motif [134, 135]. The nomenclature for the 
PDZ motif is defined as follows: the last amino acid at carboxyl terminal amino acid 
is defined as P0 residue, and subsequently, the rest of the residues towards the 
amino terminus are named as P-1, P-2, P-3, etc. [136]. Oriented peptide library 
approach was used to study the preference of amino acids within this PDZ motif 
[136]. Comprehensive previous studies indicated that the P0 and P-2 residues are 
the most critical residues for recognition and physical interaction between PDZ 
motif and PDZ domain [136]. Specific hydrophobic amino acids, Valine (V) and 
Leucine (L), are preferred at P0 position for PDZ domain recognition and binding 
[134, 137]. Meanwhile, the amino acid preference at P-2 position varies, the amino 
acid there could be hydroxylated, charged or hydrophobic [138]. Based on the 
bound PDZ motif, PDZ domains are classified into several subgroups [138, 139]. 
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Generally, they are divided into three classes: class I PDZ domains specifically 
recognize S/T-X-φ-COOH [89, 90] (φ represents hydrophobic amino acid residue 
and X represents any amino acid residue); class II PDZ domains specifically 
recognize the φ-X-φ-COOH [85, 91]; and class III PDZ domains recognize the motif 
X-X-C-COOH [140, 141]. Moreover, there are a few other PDZ domains that do 
not fit into this classification [142-144]. Proteins containing PDZ domains, such as 
Na+/H+ exchange regulatory factor 1 (NHERF1) and Na+/H+ exchange regulatory 
factor 2 (NHERF2), provide scaffold for organization of both membrane receptors 
or ion channels and downstream effectors to proximity location, leading to 
facilitated signaling transduction. Based on the status of possessed PDZ domains, 
PDZ domain containing proteins (PDZ proteins) can be divided into two groups: 
ones that only contain PDZ domain, NHERF1 and NHERF1; and proteins that 
contain PDZ domain along with other domains, such as membrane-associated 
guanylate kinase (MAGUK) proteins [82]. Within the groups of proteins that contain 
PDZ domain(s) only, NHERF1 which is also called ezrin/radixin/moesin-binding 
phosphoprotein 50 (EBP50), as well as its isoform NHERF2 are expressed in a 
variety types of cells. Possessing two highly homologous PDZ domains, PDZ1 and 
PDZ2, NHERF1 and NHERF2 provide scaffold for a variety of signaling proteins 
including GPCRs [133]. Also, both NHERF1 and NHERF2 regulate a wide range 
of cell signaling and cellular events [145]. They usually function as scaffold proteins 
to associate with membrane receptors and their downstream effectors. CXCR2 
possesses a PDZ motif (-S-T-T-L) at tis carboxyl termini, meanwhile, its 
downstream effector, PLC-β isoforms, also contain consensus PDZ motif (-X-S/T-
22 
 
 
  
X-L/V). Our previous studies have demonstrated that class I PDZ domain mediated 
multiprotein complex, including CXCR2, NHERF1, PLC-β, play important roles in 
facilitating specific and efficient signaling transduction in different cell lines [50, 96] 
(Figure 1.4).  
 
 
 
 
 
 
Figure 1.4. Structure of NHERF1 PDZ2 in complex with CXCR2 C-terminus 
containing PDZ motif and NHERF1 PDZ1 in complex with PLC-β3 C-terminus with 
PDZ motif. 
(A). Ribbon diagram of NHERF1 PDZ2 recognizes CXCR2 PDZ motif. PDZ2 is 
shown in orange and CXCR2 C-terminus peptide is shown in blue. (B). Ribbon 
diagram of NHERF1 PDZ1 recognizes PLC-β3 C-terminus peptide. PDZ1 is shown 
in green and PLC-β3 is shown in magenta. For both PDZ1 and PDZ2, the α-helices 
and β-strands are labeled according to their position in the sequence.  (Diagrams 
are modified from [146, 147]) 
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1.10. CXCR2 in angiogenesis 
Angiogenesis plays important roles in multiple biological processes, such 
as wound healing and tumor progression [148, 149]. Ligands of CXCR2 such as 
CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8 have been reported to be critical in 
promoting angiogenesis, and these findings have highlighted the significance of 
CXCR2 in angiogenesis [150-154]. Moreover, through corneal micropocket assays, 
the angiogenic activity induced by CXCR2 ligands was significantly attenuated in 
the presence of CXCR2 neutralizing antibody or under the condition of CXCR2 
depletion [155]. Meanwhile, CXCR2 has also been reported to promote endothelial 
cell tube formation, proliferation, and inhibit endothelial cell from apoptosis [156]. 
Cellular functions of endothelial cells such as migration and proliferation 
also play important roles during the process of angiogenesis. CXCL1 was reported 
to be able to enhance human umbilical vein endothelial cell proliferation [157]. It 
has also been demonstrated that CXCL1 promotes endothelial cell migration and 
proliferation through ERK1/2 and p38 MAPK signaling pathways [157, 158]. 
1.11. CXCR2 in EPC 
EPCs are defined according to expressing markers of progenitor, 
possessing the capacity of colony-forming, and being able to differentiate into 
endothelial cells. According to these characteristics, EPCs play important roles in 
blood vessel formation directly and indirectly, which contain multiple steps. The 
CXCR2 has also been detected in EPCs in previous studies and it has been shown 
that CXCR2 regulates several EPC activities such as homing, transmigration, and 
reendothelialization [51, 159, 160]. Findings from previous studies showed that 
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multiple CXCR2 ligands are positively involved in EPCs activities. It has been 
demonstrated that CXCL1 and CXCL7, function through their receptor CXCR2, 
play critical role in EPC recruitment, adhesion, and incorporation during the 
multiple steps after arterial damage [53]. More specifically, during the process of 
homing to the arterial injury sites, CXCL1 and CXCL7, promote the adhesion of 
EPCs to fibronectin or integrin ligands. Accordingly, CXCR2 is termed as an arrest 
receptor in EPCs. Compared to CXCR4, which plays critical roles in EPC 
mobilization, CXCR2 is more important during EPC recruitment [51, 159]. Another 
CXCR2 ligands, CXCL8, is also involved in CXCR2 mediated EPC transwell 
migration and capillary tube formation. Previous studies have shown that under 
hypoxic condition, upregulated expression of CXCL8 from ischemic tissue 
mediates EPC migration toward chemotaxis gradient [161, 162]. Furthermore, 
CXCL8 axis also regulates the angiogenic, proliferative, and migratory activities in 
mature endothelial cells in both paracrine and autocrine manner [156, 163]. Under 
certain pathological conditions environmental circumstances also influence the 
behaviors of EPCs, sometimes through affecting chemokines and chemokine 
receptors. In blood vessel formation related disorders, ischemia is one of the major 
environments. Hypoxic condition has been reported to upregulate the expression 
of CXCR2 and its cognate ligand, CXCL1, in EPCs. In the presence of 
CXCL1/CXCR2, the transmigration, adhesion, and angiogenic potencies of EPCs 
have been stimulated. Moreover, CXCL1/CXCR2 axis is believed to play crucial 
roles in initiating of neovascularization by recruiting EPCs [55]. Similarly, IL-8 
secreted by ischemic cardiac endothelium is also reported to function as a 
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mediator for EPC myocardial homing by generating a chemoattractant gradient 
[162]. 
1.12. Rho GTPase and RhoA/ROCK signaling  
Small GTPases are composed of a large population of hydrolase enzymes 
that function independently as molecular switches to regulate a variety of cellular 
activities. Activated by guanine nucleotide exchange factors (GEF) and inactivated 
by GTPase-activating proteins (GAP), small GTPases cycle between GTP bound 
active conformation and GDP bound inactive conformation. When they are 
activated, GTP bound GTPase will transduce signaling toward their downstream 
effectors until the GTP is hydrolyzed as shown in Figure 1.5. Among hundreds of 
GTPases, Rho, Rac, and Cdc42 belong to Rho GTPase subfamily, are the three 
most extensively studied members. Their contributions to the regulation of 
cytoskeleton assembly and regulation have been well demonstrated in a variety of 
cell lines. It has been shown that, Cdc42 and Rac are involved in mediating 
membrane protrusion while RhoA regulates the membrane retraction in fibroblasts. 
RhoA has been reported to mediate the wound closure [164, 165]. Moreover, these 
members of Rho GTPases are also associated with regulating cellular activities 
other than cell motility. They were reported to regulate cell polarity, G1 cell cycle 
progression, proliferation, and survival [166].  
Among these well studied GTPase, RhoA and its principle effector Rho-
associated kinase (ROCK)， which is a serine/threonine protein kinase, have been 
the study subjects of a variety of groups [167]. Involved in cytoskeleton 
organization, the RhoA/ROCK signaling axis has been shown to contribute to the 
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regulation of several cellular events, such as cell focal adhesion and stress fiber 
assembly [168], activation of integrin [169], migration, contraction, proliferation, 
cell cycle progression, survival, and apoptosis [170]. A growing body of evidence 
from basic research and clinical study suggest that RhoA/ROCK signaling axis play 
important roles the development of cardiac structure and conduction system during 
embryonic [171, 172]. Accordingly, RhoA/ROCK signaling pathway have been 
demonstrated to be associated with several cardiovascular diseases, including 
hypertension, coronary artery spasm, ischemic stroke, pulmonary hypertension, 
and heart failure [173-177]. Moreover, recruitment of bone marrow derived cells 
has also been attenuated under the condition of ROCK deficiency [178]. 
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Figure 1.5. Regulation of Rho GTPase activity. 
Rho GTPase cycles between GDP-bound (inactive) and GTP-bound (active) 
states. GEFs stimulates the release of GDP from Rho GTPase, which allows it to 
binding GTP. GAP hydrolysis the GTPase bound GTP to inactivate it. GDI binds 
to GDP-bound Rho GTPase to prevent it from activation and keep it away from the 
plasma membrane, which is their place for action. 
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As RhoA exerts its activities mainly through ROCK proteins to regulate a 
variety of cellular activities, ROCK proteins have also been studied. The ROCK 
family has two members, ROCK1 and ROCK2, which share 92% homology in their 
catalytic domains. Selective inhibitors, such as Y27632 [179] and fasudil [180], 
targeting ROCKs at their ATP-dependent kinase domain have been used to study 
the role of RhoA/ROCK signaling axis in different disorders. RhoA/ROCK and their 
downstream targets are responsible for cell migration and motility, and Y27632 or 
siRNA targeting ROCKs attenuated the RhoA/ROCK mediated cell migration and 
proliferation in different cell lines [181-187]. Moreover, the roles of RhoA/ROCK 
signaling axis have been extensively explored in cancer and cancer related cells, 
such as cancer associated endothelial cells [160, 188-193]. 
Under the circumstance of malignancy, decreased cell proliferation, 
migration, and invasion, as well as increased apoptosis, were observed in different 
types of cell lines when RhoA/ROCK signaling pathways were inhibited [194-200]. 
Meanwhile, different mechanisms such as reduced stress fiber and focal adhesion 
formation, decreased expression of proteolytic enzymes, and cytoskeleton 
rearrangement disorder [194, 195, 201] have been proposed to explain those 
observed results. These findings highlighted the importance of RhoA/ROCK 
signaling pathway in the cell motility, survival, proliferation, as well as gene 
expression. 
Moreover, RhoA/ROCK signaling pathway is also reported to play important 
roles in the process of blood vessel formation [202, 203]. Expressed in endothelial 
cells, RhoA/ROCK system is involved in the VEGF mediated angiogenesis, and 
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inhibiting this signaling results in impaired precapillary cords formation and 
endothelial migration [204-208]. In addition, human umbilical vein endothelial cells 
(HUVECs) overexpressing RhoA display increased migratory and angiogenic 
potency, which indicates the importance of RhoA signaling in endothelial cell 
activities [209]. Previous findings indicated that RhoA affects the endothelial cell 
functions mainly through regulating actin cytoskeleton organization [210]. In 
addition, RhoA/ROCK pathway has been suggested to be an upstream regulator 
of MAPK signaling molecules including ERK1/2, p38 MAPK, and JNK [211-213]. 
The MAPK pathways are closely associated with a variety of cellular activities [212, 
214]. To be specific, the ERK1/2 pathway, which has been well studied, is involved 
in cell growth, proliferation, differentiation, and migration [215]. Inhibition of ROCK 
decreased the activation of ERK1/2 and consequently attenuated the cell migration 
and proliferation in glioblastoma cells [214]. Recently, Zoledronate, which is used 
to treat hypercalcemia in clinic, has been shown to attenuate the angiogenesis in 
EPCs through inhibiting the activation of RhoA and MAPK signaling [216]. These 
findings suggest the association of MAPK signaling and RhoA/ROCK pathway in 
EPCs. 
On the other hand, it has been demonstrated that interfering of CXCR2 
mediated signaling transduction, either through CXCR2 neutralizing or CXCR2 
knockout, has significant effect in endothelial cell migration and angiogenesis [217, 
218]. Moreover, recruitment of EPCs from bone marrow to the sites of 
neovascularization was also reported to be mediated by CXCR2 in mice [219]. In 
addition, substantial evidence has accumulated that CXCR2 signaling activates 
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the MAPK signaling molecules, including ERK1/2, p38 MAPK, and JNK, in a 
variety of cell lines to regulate multiple cellular activities [220-223]. Interestingly, 
RhoA also plays important roles in all these blood vessel formation related cellular 
activities, such as migration, angiogenesis, and neovascularization. Taken 
together, it is possible that CXCR2 mediated angiogenesis and neovascularization 
are mediated through RhoA in endothelial cells and EPCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
  
CHAPTER 2 MATERIAL AND METHODS 
2.1. Antibodies and reagents 
Anti-human and mouse CXCR2 and PLC-β3 antibodies as well as mouse 
anti-NHERF1 monoclonal antibody were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Rabbit anti-NHERF1 polyclonal antibody was 
bought from Sigma-Aldrich. Recombinant chemokines, IL-8/CXCL8, growth-
regulated protein alpha (CXCL1/GROα/KC), and macrophage inflammatory 
protein 2 (MIP-2/murine CXCL2) as well as growth factor VEGF (both mouse and 
human) were obtained from ProSpec (East Brunswick, NJ). Growth factor reduced 
Matrigel matrix, glutathione agarose beads and Transwell inserts were purchased 
from BD Bioscience. The human and murine CXCR2 C-terminus peptides (biotin-
conjugate at N-terminus): WT (biotin-FVGSSSGHTSTTL for human CXCR2 C-tail; 
and Biotin-FVSSSSANTSTTL for mouse CXCR2 C-tail) and PDZ motif deletion 
(∆TTL) were synthesized by Genemed Synthesis, Inc. (San Antonio, TX). CXCR2 
inhibitor SB225002 was purchased from Tocris Bioscience. ChariotTM 
peptide/protein delivery reagent was purchased from Active Motif (Carlsbad, CA). 
Lipofectamine 2000, Hanks’ buffered salt solution (HBSS), Fura-2 were obtained 
from Invitrogen (Carlsbad, CA). GST PDZ fusion proteins (GST-NHERF1, 
NHERF2, or PDZK1) were purified using glutathione agarose beads (BD 
Bioscience), eluted with 50 mM glutathione, and used in pull-down. Fibronectin for 
EPCs attachment in culture plate was purchased from BD biosciences (Franklin, 
NJ).  
2.2. Plasmid, cloning, and mutagenesis 
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C-terminal fragments of murine CXCR2 (last 45 amino acids; a.a. 315–359 
for murine CXCR2) were generated by PCR cloning into pEGFP-C3 vector 
(Invitrogen). CXCR2 C-terminus PDZ motif deletion mutation (ΔTTL) was 
generated using the QuikChangeTM Site-directed Mutagenesis kit (Agilent 
Technologies), and also cloned into pEGFP-C3 vector for plasmid construction.  
2.3. EPC isolation and culture 
Mouse bone marrow (BM) cells were obtained by flushing the tibias and 
femurs from wildtype C57BL/6J mice with PBS. The collected BM mononuclear 
cells (MNCs) were isolated from collected bone marrow cells by density 
centrifugation over Histopaque1083 (Sigma). The MNCs were then collected and 
counted. Eighty million MNCs were seeded into each fibronectin (10 μg/ml) coated 
60-mm petri dish with endothelial cell basal medium-2 (EBM-2) (Lonza) 
supplemented with endothelial cell growth medium-2 (EGM-2) MV SingleQuots 
(Lonza) containing FBS (5%), vascular endothelial growth factor (VEGF), fibroblast 
growth factor-B, epidermal growth factor, insulin-like growth factor 1, 
hydrocortisone, ascorbic acid and antibiotics. Cells were cultured at 37°C with 5% 
CO2.  After 72 hours in culture, non-adherent cells were removed, and culture 
medium was changed every other day. EPCs were characterized by incorporation 
of DiI labeled acetylated low density lipoprotein (DiI-Ac-LDL) and staining of BS-
Lectin I (Vector laboratories, Burlingame, CA), and flow cytometric analysis of 
specific EPC surface markers (CD34 and VEGFR2) on day 7. During cultivation, 
the morphological changes of EPCs were recorded using inverted microscopy. 
Mouse BM-derived EPCs were also obtained from Celprogen Inc. (Torrance, CA). 
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The EPCs have been characterized by the Celprogen Company and are stained 
positive for CD34, CD45, Sca-1, AP, and demonstrate incorporation of acetylated 
LDL. The cells were maintained in EBM-2 supplemented with EGM-2 MV 
SingleQuots, and sub-cultured every 2 days on murine fibronectin-coated culture 
plates. The cells between passages 2–8 were used for the experiments. 
Cell freezing and thawing were used to maintain the early passage batches 
of cells for long term storage. Exponentially growing cells (approximately 80% 
confluency) were treated with trypsin in a 37°C incubator. Then, 3 ml growth 
medium were added to abrogate trypsin activity. The mixture was then transferred 
to a 15-ml sterile tube and centrifuged at 100g for 7 min to harvest cell pellet. The 
cell pellet was re-suspended in 5 ml freezing medium [growth medium containing 
20% FBS and 10% (v/v) dimethyl sulfoxide (DMSO)]. Then aliquots of 1ml 
containing 2 x 106 cells were transferred in cryogenic foam boxes at -80°C freezer 
overnight and then immersed in liquid nitrogen. Cells were recovered from liquid 
nitrogen by rapid thawing in a 37°C water bath, and then immediately re-
suspended in the appropriate pre-warmed culture medium and transferred to a 100 
mm2 Petri dish, and medium was changed after 24 hours. 
Human cord blood (CB)-derived EPCs (AC133 + progenitor cells) were 
isolated from the cord blood obtained from volunteers under an Institutional Review 
Board-approved protocol by the Henry Ford Health System. The cord blood MNC 
population was generated by Ficoll gradient centrifugation and was enriched for 
AC133 + cells by immune-magnetic positive selection using the MidiMACS system 
(Miltenyi Biotec, Auburn CA) according to the manufacturer's protocol. Upon 
34 
 
 
  
isolation AC133 + cells were suspended in CellGro® Stem Cell Growth Medium 
(SCGM) (CellGenix) supplemented with 40 ng/ml of stem cell factor, 40 ng/ml of 
FMS-like tyrosine kinase 3 and 10 ng/ml of thrombopoietin (all from CellGenix), as 
described before [224]. Cells were maintained under these conditions at 37°C with 
5% CO2 as a suspension culture to expand for up to 30 days with the cell 
concentration kept between 5 × 105–1 × 106 cells/ml. For cellular functional 
studies (such as adhesion and migration), primary AC133+ CB-EPC cells were first 
differentiated in EGM-2 medium supplemented with 2% FBS and 2 ng/ml of VEGF 
and plated in 6-well plate coated with human fibronectin at a concentration of 
2 × 105 cells/ml. Cells were allowed to differentiate for 2 weeks. The medium was 
changed every 2–3 days, and the cells were monitored by inverted phase contrast 
microscopy to evaluate the morphological changes during differentiation, as 
described before [224]. 
2.4. Cell adhesion assay 
ChariotTM peptide delivery reagent was used to deliver CXCR2 C-terminal 
peptides (WT and ΔTTL) into the cells as reported before for adhesion assay. 
Briefly, EPCs were cultured in fibronectin coated dishes until they reached 50% 
confluency. CXCR2 C-tail peptides (WT and ΔTTL) diluted in sterilized water were 
then mixed with ChariotTM reagent diluted in PBS at room temperature for 30 min 
to form chariot-peptide complex. The complex was then incubated with EPCs at 
37°C for 1 hour, and in the control group, EPCs were incubated with ChariotTM 
reagent only under the same condition. The cells were then detached from culture 
dish with trypsin. Ten thousand EPCs were seeded into each well of fibronectin 
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coated 96-well plate at 37°C for 1 hour in starve medium (EBM-2 medium 
containing 0.5% FBS) supplemented with 100ng/ml MIP-2. After 1 hour, non-
adherent EPCs were removed by PBS washing and attached cells were quantified 
by counting under 3 randomly selected high power field (HPF) in each well using 
an inverted microscopy. Experiment was repeated three times and each condition 
was triplicated. 
2.5. Chemotaxic migration assay 
Chemotaxic migration assay was performed using 24-well cell culture insert 
(BD bioscience) with 6.5-mm diameter polycarbonate filters (8-μm pore size) with 
EPCs. Filter membranes were pre-coated with 0.1% gelatin diluted in migration 
medium (0.5% FBS in EBM-2) for 2 h at 37 °C and air-dried afterward. EPCs in 
culture dish were delivered with CXCR2 C-terminal peptides (WT or ΔTTL) or 
ChariotTM reagent only, which was used as negative control, as described above. 
EPCs were then detached and seeded in to each culture insert.  EPCs (1 x 105) in 
100μl of migration medium (0.5% FBS in EBM-2) were loaded in the upper 
chamber of gelatin-coated Transwell, and 500μl migration medium containing MIP-
2 (100 ng/ml) was added in the lower chamber. The Transwell was then returned 
to the 37 °C incubator for 3 h to allow the EPCs to migrate toward chemoattractant 
gradient. After incubation, the remaining cells in the upper chamber were removed 
by cotton swap. The migrated cells were fixed and stained with Diff-Quick stain kit 
(IMEB, San Marcos, CA) according to the manufacturer’s protocol. Experiment 
was repeated three times and each group was triplicated. Stained adherent cells 
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were counted in 3 randomly selected fields per well using HPF under an inverted 
microscopy.  
2.6. In vitro incorporation assay 
EPCs were delivered with CXCR2 C-terminal peptides (WT or ΔTTL) or 
ChariotTM reagent alone, which was used as negative control, as described above. 
After that, EPCs were incubated with DiI-Ac-LDL (red fluorescence; Vector 
Laboratories) in growth medium or, alternatively, incubated with Calcein Am (green 
fluorescence, Invitrogen) in serum free medium according to the manufacturer’s 
protocol respectively. Fluorophore-labeled EPCs (2 x 103), delivered with different 
CXCR2 C-terminal peptides or delivery reagent, were co-cultured with human 
dermal microvascular endothelial cells (HDMECs; 1 x 104) in growth factor reduced 
matrigel (BD biosciences) coated 96-well plates (round bottomed) in EBM-2 
medium containing 100ng/ml MIP-2. The cell mixture were kept in the 37°C 
incubator for 3 hours to form tubular structure. The incorporated and non-
incorporated EPCs were quantified using ImageJ software. The percentage of 
incorporated EPCs was calculated and plotted. The proportion of EPCs in tubule 
structures was determined in 10 random fields under a fluorescence microscopy. 
2.7. Generating stable transfected EPC cell line 
EPCs were allowed to grow in culture plates till they reached 90% 
confluency which is optimum for transfection. Then the cells were transfected with 
pEGFP-C3 vector expressing different murine CXCR2 C-termini, WT and PDZ 
motif deleted, (pEGFP-CXCR2 C-tail WT and pEGFP-CXCR2 C-tail ΔTTL) or 
pEGFP-C3 vector alone into EPCs using lipofectamine 2000 reagent (Invitrogen) 
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according to the manufacturer’s instruction. Cells were allowed to grow for another 
48 hours and then were further diluted (1:1,000 dilution) and transferred into new 
culture dish. Another plate with same amount of un-transfected cells was incubated 
under the same condition as negative control. Stable expression of the constructs 
in murine EPCs were obtained by using G418 sulfate selection. The expression of 
GFP was confirmed by fluorescent microscopy and western blotting.  
2.8. In vivo matrigel plug angiogenesis assay 
EPCs stably transfected with pEGFP-CXCR2 C-tail WT and pEGFP-
CXCR2 C-tail ΔTTL or the vector only were used in matrigel plug angiogenesis 
assay. Briefly, 5 × 105 EPCs stably expressing CXCR2 C-tail constructs or vector 
alone in 100μl of PBS were mixed with 500μl of growth factor reduced Matrigel 
containing 40 units/ml heparin and 200ng/ml MIP-2. The Matrigel containing EPC 
mixtures were implanted by a single subcutaneous injection into the mid-dorsal 
region of wild-type C57BL6/J mice. Ten days after the injection matrigel plugs 
containing EPCs expressing different constructs were collected. The obtained 
matrigel plugs were prepared for histological study (H&E staining and anti-CD31 
immunostaining). Microvessel density (CD31+ cells) was quantified and compared 
in multiple mice between different groups where EPCs expressed different 
constructs. Image analyses of the areas of CD31+ blood vessels, vessel number, 
and length of vessel perimeter were carried out as reported [225]. All the animal 
studies were accomplished under the protocol approved by Wayne State 
University Institutional Animal Care and Use Committee.  
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2.9. Intracellular calcium mobilization assay 
EPCs (2 × 106/ml) were delivered with CXCR2 C-terminal peptides (WT or 
ΔTTL) or ChariotTM reagent alone as described above. The peptide-delivered 
EPCs were then labeled with 5μM Fura-2 AM in HBSS buffer (Ca2+ and Mg2+ free) 
at 37 °C for 45 min. The cells were then re-suspended in regular HBSS buffer at 
the concentration of 106 EPCs/ml. Two milliliter re-suspended EPCs were loaded 
into a continuously stirred cuvette at 37°C in a PTI fluorescence spectrophotometer 
(Photon Technology International). The fluorescence of cell suspensions was 
continuously monitored in a PTI fluorescence spectrophotometer at excitation 
wavelengths of 340 nm and 380 nm, and emission wavelength of 510 nm. The 
intracellular calcium concentration ([Ca2+]i) was expressed as the fluorescence 
ratio at 340nm and 380nm (R). EPCs were stimulated with 100ng/ml MIP-2 once 
the baseline was stabilized. At the end of each test, ionomycin (5μM, a calcium-
specific ionophore) were added to trigger maximal fluorescence ratio (Rmax). After 
that, 10mM EGTA (pH > 8) were added to chelate the Ca2+ to obtain minimum 
fluorescence ratio (Rmin). The intracellular calcium level (in nM) was proportional 
to the ratio of fluorescence at 340/380. The equation describing this relationship is 
as follows: 
[Ca2+]i (nM) = Kd x [(R – Rmin) / Rmax – R] x Sfb 
In this equation, Kd = 225 nM (under the condition that Ca2+ binds to Fura-2 AM 
at 37°C), Sfb = ratio of fluorescence at 380nm under ionomycin and EGTA treated 
conditions.   
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2.10. Pull down assay 
EPCs endogenously express CXCR2 were lysed in binding buffer (PBS + 
0.2% Triton X-100) supplemented with a mixture of protease inhibitors (containing 
1 mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 
1 μg/ml pepstatin) and phosphatase inhibitor mixture (Sigma). Cell lysates were 
mixed with the lysis buffer at 4°C for 15 min followed by centrifugation at 17, 000g 
for 15 min at 4°C. The concentration of total proteins was measured with Bradford 
method. Then the cleared supernatant was equally mixed with GST or different 
GST fused PDZ domain containing proteins (GST-NHERF1, GST-NHERF2, and 
GST-PDZK1) at 4°C for 2 h for direct binding. After 2 hours incubation, same 
amount (20ul) of glutathione agarose beads (BD biosciences, San Jose, CA) were 
equally added and mixed overnight at 4°C. Thereafter, the protein bound 
glutathione agarose beads were pelleted by low speed centrifugation (800 x g, 
1min) followed by three times of wash using lysis buffer to get rid of loosely bound 
proteins. After that, the mixture of glutathione agarose beads and proteins were 
eluted in Laemmli sample buffer containing β-mercaptoethanol. Eluted proteins 
were subjected to western blotting to detect CXCR2. 
2.11. Co-immunoprecipitation 
EPCs were solubilized in binding buffer (PBS containing 0.2% Triton X-100) 
supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 
1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin). After centrifugation 
(17,000 x g, 15 min at 4°C), cleared supernatant were collected and total protein 
concentration was measured. Then the cleared lysates were processed for co-
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immunoprecipitation using a kit for co-immunoprecipitation (Thermo Scientific). 
Resin from the kit was used to immobilize the normal IgG control and anti-CXCR2 
IgG according to the manufacturer’s instruction. Co-precipitated proteins were 
eluted in Laemmli sample buffer containing β-mercaptoethanol. Eluted proteins 
were separated by SDS-PAGE and probed for PLC-β3 and NHERF1.  
2.12. Western blot 
Denatured proteins, either from total cell lysate or from binding assay elution, 
were loaded onto Mini-PROTEAN TGX Gels (Bio-Rad) for separation. Then the 
separated proteins were transferred to polyvinylidence fluoride (PVDF) membrane 
(Bio-Rad) using Bio-Rad electrophoresis system. The transfer blot filter paper (Bio-
Rad) and the PVDF membrane (Bio-Rad) were pre-soaked in transfer buffer. 
Transfer was carried out at a constant intensity of 60V for 90 min. Following 
transfer, the membrane was then blocked in 5% non-fat dry milk solution in 1X 
TBST (Tris-Buffered Saline and Tween 20) at room temperature for 1 hour and 
incubated in primary antibody 1: 1,000 diluted with 1X TBST. Incubation was 
carried out with gentle shaking at 4ºC overnight. The membrane was then washed 
six times by gentle shaking in 1X TBST at room temperature. It was then incubated 
with a suitable secondary antibody conjugated with the horseradish peroxidase 
(HRP) 1:20,000 diluted in TBST-5% milk for 1 hour at room temperature with gentle 
shaking. The membrane was then washed in TBST. The membrane was then 
incubated with a mixture of the SuperSignal West Pico Chemiluminescent 
Substrate (Pierce) or SuperSignal West Femto maximum sensitivity substrate 
(Pierce) for 5 min at room temperature. The membrane was then exposed in UVP 
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Biospectrum 500 imaging 
system (UVP). The signals were obtained for 5 seconds to 30 minutes depending 
on the intensity of the signals and the substrate that was used. The pictures were 
processed using NIH ImageJ software. 
2.13. EPC isolation and culture 
Mouse BM-derived EPCs were obtained from Celprogen Inc. (Torrance, 
CA). The EPCs have been characterized by the Celprogen Company and are 
stained positive for CD34, CD45, Sca-1, alkaline phosphatase (AP), and 
demonstrate incorporation of Dil-Ac-LDL. The cells were maintained in EBM-2 
supplemented with EGM-2 MV SingleQuots, and sub-cultured every 2 days on 
murine fibronectin-coated culture plates. The cells between passages 2–8 were 
used for the experiments. 
Cell freezing and thawing were used to maintain the early passage batches 
of cells for long term storage. Exponentially growing cells (approximately 80% 
confluency) were treated with trypsin in a 37°C incubator. Then, 3 ml growth 
medium were added to abrogate trypsin activity. The mixture was then transferred 
to a 15ml sterile tube and centrifuged at 100g for 7 min to harvest cell pellet. The 
cell pellet was re-suspended in 5 ml freezing medium [growth medium containing 
20% FBS and 10% (v/v) dimethyl sulfoxide (DMSO)]. Then aliquots of 1ml 
containing 2 x 106 cells were transferred in cryogenic foam boxes at -80°C freezer 
overnight and then immersed in liquid nitrogen. Cells were recovered from liquid 
nitrogen by rapid thawing in a 37°C water bath, and then immediately re-
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suspended in the appropriate pre-warmed culture medium and transferred to a 100 
mm2 Petri dish, and medium was changed after 24 hours. 
2.14. Immunofluorescence staining 
EPCs were seeded on glass coverslips pre-coated with fibronectin (10μg/ml) 
until they reached 40% confluency and were starved in serum free medium before 
stimulation. EPCs were then delivered with WT CXCR2 C-terminus peptide or 
ChariotTM reagent alone before MIP-2 stimulation. At the same time, another group 
of EPCs were pre-incubated with ROCK inhibitor (Y27632) for 1 hour as negative 
control. After that the cells were then treated with 100ng/ml MIP-2 in serum free 
medium for different time spans (0, 6, 12min) followed by washing with 37°C PBS 
to remove stimulants. The cells were then fixed by 4% paraformaldehyde in PBS 
(pH = 7.0) at room temperature for 10 min and washed with PBS at room 
temperature for 30 min. The paraformaldehyde fixed cells were permeabilized in 
PBS containing 0.5% Triton X-100 for 5 mins at room temperature followed by 
washing with PBS for 30 min at room temperature to get rid of remaining detergent. 
The coverslips were then transferred to a humid chamber and were incubated with 
100nM Acti-stainTM 555 phalloidin (cytoskeleton Inc.) prepared in PBS at room 
temperature in the dark for 30min to stain F-actin. Thereafter, the nuclei were 
stained with 1μg/ml DAPI (Invitrogen) for 1 min. Then, the coverslips were washed 
with PBS and inverted on a drop of mounting media on glass slides. Pictures were 
taken under a fluorescence microscopy. 
2.15. RhoA activation assay 
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The activation status of RhoA was performed using RhoA pull-down 
activation assay kit (Cytoskeleton, Inc.) according to the manufacturer’s instruction. 
Briefly, EPCs were seeded into fibronectin coated plates till 40% confluency. Then 
EPCs were starved in serum free medium followed by incubation with 100ng/ml 
MIP-2 in serum free medium for 0, 1, 3, 6min. After chemokine stimulation, medium 
was aspired and cells were washed with PBS followed by aspiration of PBS. Ice-
cold lysis buffer provided by the kit was used to lyse the cells. After that, cell lysate 
from each group were collected by cell scraper and clarified by centrifugation (10, 
000 x g, 1 min at 4°C). After measurement of protein concentration, 25ug cell lysate 
from each group was obtained and used as input and 400ug total cell lysate from 
each group was used for pull-down assay. Same amount (50ug) rhotekin-RBD 
beads, which specifically binds to activated RhoA, were used for pull-down in each 
group. Binding was carried out at 4°C for 1 hour then the beads were pelleted. 
When the binding was completed, the rhotekin-RBD beads were pelleted. The 
proteins bound to the beads were eluted in Laemmli sample buffer containing β-
mercaptoethanol and boiled for 2 min. The eluted and denatured proteins were 
then subjected to western blot to detect the bound activated RhoA as previous 
mentioned except for the equilibration step. The equilibration was performed after 
electrophoresis. During equilibration, the gel was immersed in western blot buffer 
(containing 25mM Tris pH 8.3, 192mM glycine, and 15% methanol dissolved in 
water).  
2.16. MAPK and Akt signaling activation assay 
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EPCs were cultured in fibronectin coated 6-well plates to reach 80% 
confluency and were starved in serum free medium before stimulation. After 
starvation, EPCs were delivered with WT CXCR2 C-terminus peptide or ChariotTM 
reagent alone. Meanwhile, another group of EPCs were pre-incubated with 10μM 
ROCK inhibitor Y27632 for 1 hour. Then cells from each group were stimulated 
with 100ng/ml MIP-2 for different time spans (0, 1, 3, 6, and 12 min). Cells were 
then washed with PBS to remove any remaining chemokines and were solubilized 
in RIPA buffer (150 mM NaCl, pH 8.0, 50 mM Tris-base, 1% (v/v) Nonidet P-40, 
0.5% (v/v) Na-deoxycholate, 0.1% (v/v) SDS) supplemented with protease inhibitor 
cocktail (1 mM phenylmethylsulfonyl fluoride, 1 μg/ml of aprotinin, 1 μg/ml of 
leupeptin, and 1 μg/ml of pepstatin) and a mixture of phosphatase inhibitors 
(40mg/ml sodium fluoride, 20mg/ml sodium orthovanadate, and 65mg/ml sodium 
pyrophosphate). Cells were lysed in 4°C for 15 min and were centrifuged to pellet 
nuclei and cell debris. Cleared supernatant were collected and total protein 
concentration was measured in each sample with Bradford method. After 
concentration measurement, 20μg of each sample were mixed with Laemmli 
sample buffer containing β-mercaptoethanol. Denatured proteins were subjected 
to western blot to detect phosphorylation status of signaling molecules belonging 
to MAPK pathway, such as Akt, JNK, p38MAPK, and ERK1/2. 
2.17. Statistical analysis 
            All experiments are repeated at least three times. Analyzed data is 
presented as mean ± SE. Statistical significance of differences was evaluated with 
student’s t-test. When p < 0.05, the data was considered as statistically significant. 
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CHAPTER 3 RESULTS 
3.1. CXCR2 PDZ-mediated macromolecular complex in EPC homing and 
angiogenesis  
3.1.1. Rationale 
Angiogenesis, which is composed of endothelial cells migrate from pre-
existing blood vessels and proliferate to form blood vessels, was believed to be 
the only mechanism of new blood vessel formation until Asahara and his 
colleagues isolated EPCs twenty years ago [26, 226, 227]. Despite the debate of 
EPC characterization and definition, our knowledge of EPCs biology has 
extensively improved during the past two decades. Based on the morphological 
and functional features, EPCs can be generally divided into two groups: early 
EPCs and late EPCs. Early EPCs, which exist at the early stage in culture, possess 
spindle shape and contribute to angiogenesis by producing angiogenic cytokines 
such as IL-8 and VEGF. Late EPCs display cobblestone shape and express 
different cell surface markers. Moreover, late EPCs with the potential of long term 
proliferation, are able to incorporate into endothelial network and differentiate into 
mature endothelial cells to facilitate new blood vessel formation [2, 20, 228-230]. 
Findings from preclinical studies have demonstrated the contribution of early and 
late EPCs to the blood vessel formation under the condition of ischemia [25, 32]. 
It has been shown that these two groups of cells synergistically promote the 
neovascularization, mainly through IL-8 secretion, when infused together into 
animal model [32]. Due to the roles that EPCs play during angiogenesis and 
neovascularization in a variety of disorders [12, 53, 231-234], they have been 
considered to be a potential therapeutic target. However, administration of EPCs 
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in clinical studies seems not fully encouraging [235]. Accordingly, deep 
understanding of EPC biology, especially the underlying molecular mechanism of 
the angiogenic and vasculogenic functions in EPCs, will significantly improve the 
translational study. 
It has been reported that both CXCR2 neutralizing antibody and CXCR2 
depletion dramatically decreased endothelial cell migratory and angiogenic 
capacities [217, 218]. Moreover, recruitment of EPCs from bone marrow to the 
sites of neovascularization was also reported to be mediated by CXCR2 in mice 
[219]. These studies have revealed the importance of CXCR2 in regulating cellular 
functions during angiogenesis and neovascularization. Importantly, our recent 
studies have further demonstrated that the PDZ motif located at the C-terminus of 
CXCR2 is involved in regulating intracellular signaling transduction and cellular 
functions in neutrophil and pancreatic cancer cells [50, 96]. In our studies, we 
showed that NHERF1, a scaffolding protein containing two PDZ domains, 
clustered CXCR2 and its downstream signaling molecule PLC-β to form 
macromolecular complex through PDZ mediated protein-protein interactions in 
neutrophil and pancreatic cancer cells. These multiprotein complexes were 
involved in a variety of cellular activities, such as cell migration, proliferation, and 
calcium mobilization. Therefore, it is possible that the CXCR2, through its PDZ 
motif, can also interact with PDZ domain containing scaffolding proteins, which 
further interact with other downstream proteins to form multiprotein complex in 
EPCs. However, the existence of this PDZ mediated CXCR2 involved 
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macromolecular complex as well as its influence in EPCs have not been evaluated 
so far.  
3.1.2. Results 
3.1.2.1. EPC isolation and characterization 
In addition to using commercially available mouse EPCs (Celprogen Inc.), 
EPCs were isolated from the tibias and femurs of C57BL/6J according to the 
protocols previously reported [13, 29]. Isolated EPCs were cultured in EPC specific 
medium for in vitro expansion. After 4 days of cultivation, the isolated EPCs 
gradually adhered to the fibronectin coated growing surface and displayed spindle-
shaped morphology as shown in Figure 3.1.1A, which is similar to the morphology 
reported by Asahara as well as others [2, 236]. Those attached cells were 
characterized by DiI-Ac-LDL up-taking and FITC-conjugated BS-Lectin staining as 
shown in Figure 3.1.1B. AC133+ EPCs isolated from human cord blood were also 
cultured according to previously reported protocol [224] as shown in Figure 3.1.1C.  
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Figure 3.1.1. EPC isolation and characterization.  
(A). Morphology of EPCs isolated from mice bone marrow (BM-EPCs) in culture at 
day 1, 7, and 14 (phase contrast images, 4x or 10x magnificent). (B). Images for 
phase contrast, DiI-Ac-LDL (red) up-taking and FITC conjugated BS-Lectin I 
(green), and nuclei staining (DAPI, blue) of bone marrow derived EPCs (10x 
magnificent). (C). Morphology of EPCs isolated from human cord blood in cell 
culture at day 1, 14, and 28 in cell culture (10 x magnificent). 
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3.1.2.2. CXCR2 signaling plays important roles in EPC migration and 
angiogenesis in mice. 
EPCs need to migrate toward and subsequently adhere to the angiogenic 
active site to contribute to the formation of new blood vessels and CXCR2 is also 
reported to be important in regulating angiogenesis. The role of CXCR2 was 
evaluated in these processes in EPCs, including EPC migration, adhesion, 
invasion, and incorporation into endothelial network. The commercially available 
murine EPCs (Celprogen Inc.) were used in these experiments. The data shows 
that compared with controls, EPCs, which were cultured in basal medium (EBM-2 
containing 0.5% FBS), VEGF (used as positive control), MIP-2, and CXCL8 
treatment significantly improved EPC migration (Figure 3.1.2), adhesion (Figure 
3.1.3), invasion (Figure 3.1.4), and incorporation into endothelium tubular structure 
(Figure 3.1.5) as shown in Figures respectively. On the other hand, MIP-2 and 
CXCL8 mediated EPC migration, adhesion, incorporation into endothelium 
network, and tubular structure formation were significantly attenuated by inhibiting 
CXCR2 mediated signaling transduction through CXCR2 neutralizing antibody 
[237] or CXCR2 antagonist SB225002 [238]. However, the promotive activities 
generated by VEGF were not affected by CXCR2 signaling interfering, which is 
consistent with previous findings [51, 219].  
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Figure 3.1.2 CXCR2 promotes murine EPCs migration. 
Pictures (A) and Bar graphs (B) showed MIP-2, CXCL8, and VEGF (all 100ng/ml) 
prmoted the migration of EPCs (pre-treated in goat serum); CXCR2 antiserum 
(EPCs pre-treated with neutralizing antibody in goat serum) inhibited the MIP-2 
and CXCL8 mediated EPCs migration but VEGF mediated EPC migration was not 
affected (n=4, p < 0.05). (C) EPC migration was improved by MIP-2, CXCL8, and 
VEGF (all 100ng/ml) and the promotive effect of MIP-2 and CXCL8 could be 
inhibited by pre-incubation with CXCR2 antagonist SB225002. While VEGF 
mediated increased migration was not affected by the CXCR2 antagonist pre-
incubation (n=4, p < 0.05). (NT: no cytokine treatment, HPF: high power field).  
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Figure 3.1.3. CXCR2 promotes murine EPC adhere to fibronectin. 
Pictures (A) and bar graph (B) showed that MIP-2, CXCL8, and VEGF promoted 
EPC adhere to fibronectin coated surface compared with EPCs without stimulation 
(NT: no cytokine treatment). Pre-incubation of CXCR2 antiserum (goat serum 
containing CXCR2 neutralizing antibody) significantly inhibited MIP-2 and CXCL8 
promoted EPC adhesion but had not effect on VEGF promoted ECP adhesion to 
fibronectin. (n=3, p< 0.05) 
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Figure 3.1.4. CXCR2 promotes EPC invasion activity in vitro. 
MIP-2, CXCL8, and VEGF (all 100ng/ml) facilitate the invasion of EPCs through 
matrigel. The administration of CXCR2 antagonist SB225002 significantly 
attenuated the promotive effect generated by MIP-2 and CXCL8 while had no 
effect on VEGF promoted EPC invasion. (n=4, p < 0.05).  
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Figure 3.1.5. CXCR2 promotes the incorporation of EPCs into endothelial network 
in vitro. 
DAPI labeled EPCs (blue), pre-incubated in goat serum, incorporation into 
endothelium (HDMEC shown as transparent cells) tubular network in matrigel was 
significantly improved by CXCR2 ligands, MIP-2 and CXCL8, and VEGF as shown 
in fluorescent images (A) and bar graph (B).  Pre-incubation of EPCs in CXCR2 
antiserum significantly reduced the EPCs incorporation into endothelium tubule 
structures in response to CXCR2 ligands, but had no apparent effect on VEGF 
promoted increased incorporation. (n=4, p < 0.05). 
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Human cord blood derived EPCs were also used to confirm the findings in 
murine EPCs. Accordingly, the role of CXCR2 in human EPC migration and 
incorporation into endothelial tubular structures were evaluated respectively. 
Human cord blood EPCs were obtained as reported [224, 239-241]. The result 
suggested that the migratory potential and the ability of incorporating into 
endothelial tubular structure of EPC were increased in response to the CXCL8 and 
VEGF compared to that of the cells without any treatment. Moreover, when EPCs 
were pre-incubated with CXCR2 antagonist SB225002, the promotive effect of 
CXCL8 on EPCs were significantly reduced, while promotive effect of VEGF on 
EPCs were not apparently affected (Figure 3.1.6). These findings were consistent 
with those from murine EPCs. 
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Figure 3.1.6. CXCR2 promotes human EPC migratory and incorporative capacities 
in vitro. 
(A). Migration of human cord blood derived EPCs was promoted by CXCL8 and 
VEGF (all 100ng/ml). The increased migration mediated by CXCL8 treatment was 
significantly interfered by pre-incubation of EPCs with CXCR2 antagonist 
SB225002 but that mediated by VEGF was not affected (n=4, p < 0.05). (B) EPCs 
in vitro incorporation into HDMVEC tubule structure was facilitated by CXCL8 and 
VEGF treatment (all 100ng/ml). The promoted incorporation mediated by CXCL8 
was attenuated by pre-incubation with CXCR2 antagonist SB225002 but mediated 
by VEGF was not affected significantly (n =3, p < 0.05) (NT: not cytokine treated, 
SB: SB225002). 
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3.1.2.3. Disrupting CXCR2 PDZ motif-mediated interactions inhibits EPC in 
vitro adhesion. 
Our previous studies have demonstrated the importance of CXCR2 PDZ 
motif (TTL) in facilitating CXCR2 mediated intracellular signaling transduction in 
neutrophil and pancreatic cancer cells [50, 96]. It has been demonstrated that 
CXCR2 is actively involved in EPC homing and angiogenesis [51, 219]. So it is 
possible that the PDZ motif of CXCR2 is also involved in the CXCR2 mediated 
EPC activities including migration, adhesion, invasion, and incorporation into 
endothelial cell network. For this purpose, synthesized biotin labeled CXCR2 C-
terminus containing PDZ motif (Biotin-FVSSSSANTSTTL; WT) or without PDZ 
motif (Biotin-FVSSSSANTS; ΔTTL) were used for EPC functional assays in vitro. 
Murine EPCs were firstly delivered with different CXCR2 C-terminal peptides (WT 
or ΔTTL) or the delivery reagent alone (ChariotTM) and then were seeded onto 
fibronectin coated culture dishes in starve medium (EBM-2 containing 0.5% FBS) 
supplemented with or with MIP-2 (100ng/ml). After 1 hour, adherent cells were 
counted. The result showed that the adhesion of WT CXCR2 C-terminus peptide 
delivered EPCs to fibronectin in response to MIP-2 was significantly attenuated 
compared to that of EPCs delivered with ChariotTM or ΔTTL CXCR2 C-terminus 
peptide (Figure 3.1.7A).  The same concept was also evaluated in human cord 
blood derived EPCs. Human cord blood derived EPCs were delivered with human 
CXCR2 C-terminus peptides with or without PDZ motif (WT or ΔTTL) or ChariotTM 
alone. Then those cells were used for adhesion assay mediated by CXCL8. The 
data showed that WT peptide delivery significantly inhibited the human cord blood 
derived EPCs adhesion to fibronectin under the stimulation of CXCL8 (Figure 
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3.1.7B). These findings indicated that PDZ motif of CXCR2 plays an important role 
in EPC adhesion. 
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Figure 3.1.7. WT CXCR2 C-terminus peptides delivery inhibited EPCs adhesion to 
fibronectin mediated by CXCR2 signaling. 
(A). Picture and bar graph of murine EPCs delivered with WT or ΔTTL CXCR2 C-
terminus peptide, or ChariotTM reagent alone for adhesion assay under the 
stimulation of MIP-2. WT peptide delivery significantly decreased the EPC 
adhesion to fibronectin. (n = 4, p < 0.05) (B). Human cord blood derived EPCs 
were also delivered with human WT or ΔTTL peptide or delivery reagent alone for 
adhesion assay under the stimulation of CXCL8. WT peptide significantly 
attenuated the EPC adhesion to fibronectin compared to those deliveries with 
ΔTTL peptide or ChariotTM reagent alone. (n = 4, p < 0.05) 
59 
 
 
  
 
3.1.2.4. Disrupting CXCR2 PDZ motif-mediated interactions inhibits EPC in 
vitro migration 
Transwell migration assay were performed using both murine EPCs and 
human cord blood derived EPCs. Similarly, EPCs were subject to delivery of 
CXCR2 C-terminus peptides (WT or ΔTTL) or ChariotTM alone followed by 
transwell migration assay. The results from transwell migration assay showed that 
EPCs delivered with WT peptides displayed significantly reduced migratory 
potential under the stimulation of MIP-2 or CXCL8, which was not observed in 
EPCs delivered with ΔTTL peptides (Figure 3.1.8). These data indicated that 
CXCR2 PDZ motif is important in EPC migratory activity in both human and mice. 
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Figure 3.1.8. WT CXCR2 C-terminus peptides delivery inhibited EPCs migration. 
(A). Picture and bar graph of murine EPCs delivered with WT or ΔTTL CXCR2 C-
terminus peptide, or ChariotTM reagent alone for migration assay under the 
stimulation of MIP-2. WT peptide delivery significantly decreased the MIP-2 
induced EPC migration. (n = 4, p < 0.05) (B). Human cord blood derived EPCs 
were also delivered with human WT or ΔTTL peptide or delivery reagent alone for 
migration assay under the stimulation of CXCL8. WT peptide significantly 
attenuated the EPC migration compared to that delivery with ΔTTL peptide or 
ChariotTM reagent alone. (n = 4, p < 0.05) 
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3.1.2.5. Disrupting CXCR2 PDZ motif-mediated interactions blocks EPC in 
vitro incorporation into endothelial tubule structure. 
It has been suggested that EPCs need to act in concert with pre-existing 
endothelial cells to form blood vessels, but not to form new vessels de novo [64]. 
In addition, it has also been documented that CXCR2 neutralizing antibody 
dramatically attenuated the incorporation of human EPCs into the arterial injury 
site in the carotid arteries of athymic nude mice [51], indicating that CXCR2 play 
an important role in the process of EPC incorporation. In order to evaluate the role 
of CXCR2 PDZ motif-mediated interactions in the process of EPC incorporation 
into endothelial tubular structure, CXCR2 peptides (WT or ΔTTL) or ChariotTM were 
delivered into EPCs. After that, the cells were labeled with DiI-Ac-LDL and were 
cultured with HDMECs in growth factor reduced matrigel respectively in the 
presence of MIP-2. The result showed that WT peptide delivery significantly 
interfered the incorporation of EPCs into endothelial tubular structure while ΔTTL 
peptide delivery did not significantly affect the EPC incorporation induced by MIP-
2. (Figure 3.1.9) 
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Figure 3.1.9. Disrupting PDZ-mediated interaction attenuated the incorporation of 
EPCs to the endothelial tubular network 
WT CXCR2 C-terminus peptides delivery significantly reduced the incorporation of 
EPCs into the endothelial tubular network. While ΔTTL peptide delivery did not 
achieve any significant inhibition on EPC incorporation compared to control group 
which delivered with ChariotTM reagent alone. (n=3, p< 0.05) 
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3.1.2.6. Disrupting CXCR2 PDZ motif-mediated interactions decreases EPC 
in vivo angiogenesis in mice. 
EPCs have been reported to contribute to neovascularization through 
incorporating into the vessel formation site and differentiating into mature 
endothelial cells [242, 243]. In order to investigate the role that PDZ motif of 
CXCR2 plays in EPC neovascularization in vivo, matrigel plug assay was 
performed using murine EPCs. For this purpose, EPCs that stably express CXCR2 
C-terminus peptide were established. Constructs expressing CXCR2 C-terminus 
peptides that contains the last 45 amino acids of CXCR2 were cloned into pEGFP-
C3 vector (pEGFP-CXCR2 C-terminus WT). The PDZ motif deleted mutation 
(pEGFP-CXCR2 C-terminus ΔTTL) was also generated with commercial available 
mutagenesis kit. The generated constructs and empty vector (pEGFP-C3) were 
then delivered into EPCs with lipofectamine 2000 separately. Stable cell lines 
consistently expressing transfected constructs were obtained by G418 selection. 
The expression of the constructs was evaluated by fluorescent microscopy and 
western blot as shown in Figure 3.1.10.  
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Figure 3.1.10. Stable cell lines expressing CXCR2 C-terminus peptides or GFP 
only. 
(A). Pictures of EPCs expressing pEGFP-C3 CXCR2 C-terminus WT or ΔTTL 
under fluorescent microscopy. (B). Western blot detecting the expression of GFP-
CXCR2 C-terminus WT or ΔTTL peptides or GFP alone in EPC cell lysates (IB: 
GFP). 
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When the stable cell lines were established, the cells were used for matrigel 
plug assay. EPCs expressing different CXCR2 C-terminus constructs were mixed 
with growth factor reduced matrigel containing MIP-2. The matrigel containing 
EPCs were subcutaneously injected into wildtype C57BL/6J mice. Ten days after 
administration, the matrigel plugs were obtained and prepared for histological 
investigations. Visually, less blood vessels were observed from the matrigel plug 
containing EPCs expressing WT CXCR2 C-terminus compared to those containing 
EPCs expressing vector alone or ΔTTL CXCR2 C-terminus. The matrigel plugs 
were then subjected to H&E staining and immunohistochemistry (IHC) staining. 
Data from H&E staining showed that the tubular structure formation was 
significantly decreased in matrigel plugs containing pEGFP-C3 CXCR2 C-terminus 
WT transfected EPCs compared with those containing EPCs expressing ΔTTL 
CXCR2 C-terminus (Figure 3.1.11A). The expression of endothelial marker, CD31, 
in the matrigel was also evaluated. The data from IHC demonstrated that the 
expression of CD31 was significantly lower in WT group compared with ΔTTL 
group (Figure 3.1.11B). The microvessel density represented by CD31+ cells were 
quantified and compared among groups. The result showed that the microvessel 
number in the matrigel from WT group was significantly lower than that from ΔTTL 
and vector control groups (Figure 3.1.11C). The plugs from WT and ΔTTL groups 
were homogenized and the homogenates were used for western blot to confirm 
the expression of GFP fused CXCR2 C-terminus peptide (Figure 3.1.11D).  
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Figure 3.1.11. Disrupting CXCR2 PDZ motif-mediated interactions reduces EPC 
in vivo angiogenesis in mice 
(A). H&E staining of newly formed blood vessels (arrows) in matrigels containing 
EPCs transfected with pEGFP CXCR2 WT (left) or ΔTTL (right) C-termini. (B). IHC 
staining of CD31 in matrigels containing EPCs expressing pEGFP CXCR2 WT (left) 
or ΔTTL (right) C-termini. (C). Quantification of CD31 positive blood vessels in 
matrigel plugs from matrigels with EPCs expressing pEGFP CXCR2 WT (left) or 
ΔTTL (right) C-termini. (n= 5 mice in each group, p< 0.01) (D). Western blot using 
anti GFP antibody to detect the expression of GFP fused CXCR2 WT (left) and 
ΔTTL (right) C-terminus. 
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3.1.2.7. Disrupting CXCR2 PDZ motif-mediated interactions reduces 
CXCR2-mediated EPC intracellular calcium mobilization 
CXCR2 is able to couple to the pertussis toxin-sensitive Gi proteins to 
stimulate phospholipase C (PLC) activities [50]. GPCR-induced PLC activation 
catalyzes the hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2), resulting 
in two second messengers: diacylglycerol (DAG) and inositol-1,4,5-trisphosphate 
(IP3) which can trigger the intracellular calcium mobilization [244]. It is well 
accepted that calcium signaling plays important roles in cytoskeletal reorganization 
and cell migration [245, 246]. Recently, it has been reported that calcium signaling 
is involved in the EPC migration toward the sites of neovascularization and 
vascular remodeling [247]. In order to study the role of CXCR2 PDZ-mediated 
interaction in calcium signaling in the cells, intracellular calcium mobilization assay 
was performed in vitro. CXCR2 C-terminus peptides (WT or ΔTTL) or ChariotTM 
reagent alone were delivered into murine EPCs separately. Then calcium 
mobilization under the stimulation of MIP-2 (100ng/ml) was performed and the 
results were calculated as described in the method. The result demonstrated that 
the MIP-2 induced calcium mobilization was significantly attenuated in EPCs 
delivered with WT CXCR2 C-terminus peptide, but not in those delivered with 
ΔTTL CXCR2 C-terminus peptide or ChariotTM reagent alone (Figure 3.1.12). 
These data suggested that PDZ-mediated interaction plays an important role in 
calcium mobilization in EPCs.  
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Figure 3.1.12. Disrupting CXCR2 PDZ-mediated interactions attenuated MIP-2 
induced calcium mobilization in EPCs. 
EPCs were delivered with different CXCR2 C-terminus peptide (WT or ΔTTL) or 
ChariotTM respectively and were treated with MIP-2 (100ng/ml) to induce calcium 
mobilization. The cells were incubated with Fura-2 (5μM) and the fluorescence was 
monitored in a PTI fluorescence spectrophotometer under different wavelength. 
The changes of intracellular calcium level (nM) in different groups were obtained 
and calculated as previously described (Wu et al., 2012). (n=4, p < 0.01). 
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3.1.2.8. CXCR2 interacts with relevant signaling proteins via PDZ-based 
interactions. 
CXCR2 processes a consensus PDZ motif (-STTL-COOH) at its carboxyl 
terminus, which could potentially bind to certain proteins containing PDZ motif. 
Based on PDZ array (Panomics) and previous studies [50, 96] several PDZ 
scaffold proteins which interact with CXCR2 through its C-terminal PDZ motif have 
been identified. GST pull-down assay was performed to investigate whether 
endogenous CXCR2 in EPCs interacts with PDZ scaffold proteins as previously 
described [50]. EPCs were lysed and cleared cell lysate were incubated with GST 
fused PDZ proteins (GST-NHERF1, GST-NHERF2, and GST-PDZK1) or GST for 
binding. After that, the GST-fusion proteins with their bound proteins were pull-
down by glutathione agarose beads for western blot to detect CXCR2. The result 
demonstrated that CXCR2 was pulled down by NHERF1 rather than NHERF2 or 
PDZK1 (Figure 3.1.13A), indicating that endogenous CXCR2 prefers to interact 
NHERF1 in EPCs. In order to investigate if the binding between NHERF1 and 
CXCR2 happens endogenously, co-immunoprecipitation assay was performed. 
EPCs were lysed and cleared cell lysate were used for co-immunoprecipitation 
according to the instruction of manufacturer. The result showed that endogenous 
NHERF1 could be co-immunoprecipitated with CXCR2 in EPCs (Figure 3.1.13B). 
As introduced above, CXCR2 couples to Gi, which is sensitive to pertussis 
toxin, to active PLC-β isoforms. In addition, we have demonstrated that PLC-β2 
forms multiprotein complex with CXCR2 and NHERF1 through PDZ-based 
interaction in neutrophils [50]. We have also reported a NHERF1 interact with PLC-
β43 and CXCR2 to form macromolecular complex in a PDZ dependent manner in 
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pancreatic cancer cells [96]. More importantly, it was reported that PLC-β2 
deficiency in EPC results in interfered migration and intracellular calcium 
mobilization [247]. As demonstrated above, disrupting PDZ-mediated interactions 
attenuated CXCR2 mediated calcium mobilization in EPCs, which suggests that 
PLCβ isoform may form macromolecular complex with CXCR2 through PDZ based 
interaction. For this purpose, co-immunoprecipitation assay was performed using 
CXCR2 antibody. The data demonstrated that PLC-β3 was co-immunoprecipitated 
with CXCR2 (Figure 3.1.13C). Like CXCR2, PLC-β3 also contains a PDZ motif at 
its C-terminus [96], so it is highly possible that NHERF1, possessing two PDZ 
domains, functions as a scaffold protein to cluster CXCR2 and PLC-β3 to proximity 
to form a macromolecular complex through PDZ-mediated interactions to facilitate 
specific and efficient signaling transduction in EPCs. 
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Figure 3.1.13. CXCR2 interact with NHERF1 and PLC-β3 through PDZ-mediated 
interactions. 
(A). endogenous CXCR2 was pulled down by GST NHERF1 protein. (B). 
Endogenous NHERF1 was co-immunoprecipitated with endogenous CXCR2 in 
EPC. (C). Endogenous PLC-β3 was co-immunoprecipitated with endogenous 
CXCR2 in EPC. 
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3.1.3. Discussion 
A large body of evidence has accumulated to indicate that EPCs, which is 
considered to be a group of cells that are derived from bone marrow, have the 
capacity to migrate, proliferate, and differentiate from progenitor phenotype into 
mature endothelial cells in a variety of systems. EPCs have been demonstrated to 
be important in adult neovascularization and contribute to vascular repair as well 
as tumor growth [2, 248]. The homing of EPCs toward the new blood vessel 
formation sites is a complex process which includes chemotactic migration, 
invasion, adhesion, incorporation, and finally differentiation [243]. These 
processes are regulated by a variety of biologically active factors such as cytokines, 
chemokines, and growth factors. During two decades of investigation of EPC 
biology, CXCR2 and CXCR4 and their ligands have been reported to play critical 
roles in EPC homing through regulating EPC mobilization, recruitment, and firm 
adhesion injury [51, 162, 219, 249-251]. Although EPCs have been studied for two 
decades in different areas, the underlying mechanisms of how EPCs contribute to 
postnatal neovascularization still needs further investigation. 
CXCR2 possesses a PDZ motif at its C-terminus, and the PDZ motif has 
been reported to modulate CXCR2 mediated cellular chemotaxis [252]. We have 
recently demonstrated the role of PDZ mediated CXCR2 involved macromolecular 
complex in neutrophil and pancreatic cancer cells. In neutrophils, disrupting PDZ-
mediated interaction by exogenous peptide (short peptide containing CXCR2 PDZ 
motif) significantly interrupted CXCR2-mediated calcium mobilization and 
migration [50]. Similarly, in pancreatic cancer cells, introducing exogenous peptide 
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containing CXCR2 PDZ motif has significantly attenuated proliferation and 
invasion in vitro and inhibited tumor growth in vivo [96]. 
In this study, the importance of CXCR2 PDZ-mediated interaction in EPC 
motility and angiogenic potency has been demonstrated through functional assays 
and biochemical studies. Through introducing exogenous CXCR2 C-terminus 
peptide (WT or PDZ motif deleted) or stably transfecting DNA constructs 
expressing CXCR2 C-terminal fragments into EPCs, the CXCR2 PDZ-mediated 
interactions have been interrupted. Consequently, the abilities of EPCs 
incorporating into endothelium network (Figure 3.1.9) and postnatal 
neovascularization (Figure 3.1.11) was significantly interfered. Moreover, the 
intracellular calcium mobilization was also affected due to the interrupted CXCR2 
PDZ-mediated interaction (Figure 3.1.12). Based on our previous findings, these 
results indicated that a PDZ-mediated CXCR2 involved multiprotein complex may 
be formed in EPCs to regulate those cellular activities. A growing body of evidence 
indicate that proteins containing PDZ domains function as scaffolding proteins to 
cluster multiple proteins to form macromolecular complexes which promote 
specific and efficient signaling transduction [145, 253-255].  
It has been reported that antiserum against the PDZ motif of shCD146, 
which is a cell adhesion molecule, inhibited the adhesion of EPCs to activated 
endothelial cells. This study indicated that PDZ motif plays important roles in EPC 
biology [256]. Recently, we have also demonstrated that NHERF1 clustered 
CXCR2 and PLC-β to proximity in neutrophil and pancreatic cancer cells to 
regulate CXCR2 mediated signaling transduction [50, 96]. We further reported the 
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crystal structures that demonstrated the interaction between NHERF1 and CXCR2 
as well as NHERF1 and PLC-β3 [146, 147, 257]. PLC-β isoforms have been 
documented to be involved in GPCR-mediated cellular activities. Among the 4 
members of PLC-β family, PLC-β3 is widely expressed in different tissues [258] 
and can be activated by Gβγ subunits [259]. PLC-β3 has been reported to interact 
with PDZ domain containing proteins including NHERF1 and NHERF2 through the 
PDZ motif located at its C-terminus in a variety of cell lines [260-262]. Based on 
these findings, it is reasonable to speculate that the PDZ-mediated CXCR2 
involved multiprotein complex may also exist in EPCs to regulate signaling 
transduction. In the present study, the biochemical assay demonstrated that in 
EPCs NHERF1 clustered CXCR2 and PLC-β3 to form macromolecular complex. 
Accumulating evidence suggested that the assembly of the macromolecular 
complex beneath cellular membrane facilitated the transduction of signals from 
environment into the cells, which subsequently affected the cellular activities 
specifically and efficiently [50, 263-266]. Furthermore, functional assays 
suggested the importance of this multiprotein complex in EPC recruitment and 
incorporation into endothelial tubule structure. 
These findings suggested a therapeutic implication of PDZ-mediated 
CXCR2 involved multiprotein complex in diseases related to blood vessel 
formation. EPCs are involved in a variety of disorders including pathologic 
angiogenesis, tumor progression, and airway remodeling in asthma [219, 249, 267, 
268]. Therefore, inhibiting the angiogenic potency of EPCs may provide an 
approach to control new blood vessel formation in these disorders. In vivo matrigel 
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plug assay has demonstrated that competing the PDZ-mediated interaction 
between CXCR2 and NHERF1 by introducing CXCR2 C-terminus peptides into 
EPCs has significantly hindered the EPC involved blood vessel formation. These 
findings have supported the notion that targeting PDZ-mediated interaction in EPC 
may have therapeutic implication in angiogenesis related diseases. In addition, 
Aarts et al. reported that disrupting the PDZ based interaction between N-methyl-
D-aspartate receptor (NMDAR) and PSD-95 has inhibited the activation of 
neuronal nitric oxide synthase (nNOS), which subsequently reduced the stroke 
induced brain injury [269]. Moreover, the PDZ domain of adaptor protein PICK1 
has recently been identified as a potential therapeutic target for neuropathic pain, 
excitotoxicity, and cocaine addiction [270, 271]. Therefore, targeting PDZ-
mediated CXCR2 involved macromolecular complex in EPC may convey 
promising therapeutic implication in diseases associated with blood vessel 
formation such as tumor progression. 
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3.2. RhoA is involved in CXCR2 signaling in EPC 
3.2.1. Rationale 
Substantial proof has accumulated that CXCR2 signaling activates the 
MAPK signaling molecules, including ERK1/2, p38 MAPK, and JNK, in a variety of 
cell lines to regulate multiple cellular activities [220-223, 272]. It is well accepted 
that MAPK signaling pathway regulates cell migration in cancer cells [273], 
endothelial cell [274], and EPCs [216]. MAPK signaling is important in the process 
of angiogenesis due to its contribution to the migratory and proliferation in 
endothelial cells and EPCs, which are critical events in angiogenesis. On the other 
hand, the regulatory effects of CXCR2 on the motility and angiogenic activities in 
EPCs has been reported as well. Li et al. also reported that EPC mobilization and 
neovascularization were significantly hindered in CXCR2 knockout mice [45]. 
Furthermore, the promotive role of CXCR2 in angiogenesis have been well 
appreciated [217, 275]. These findings indicate the putative involvement of MAPK 
signaling in the CXCR2 regulated EPC functions. 
Another important signaling effector downstream of CXCR2 is PI3K/Akt. It 
has been demonstrated that PI3K/Akt and MAPK are involved in CXCR2 mediated 
actin remodeling in neutrophil [276]. Moreover, PI3K/Akt signaling is also involved 
in CXCR2 mediated chemotaxis and the process of epithelial-mesenchymal 
transition (EMT) [277, 278]. More importantly, PI3K/Akt has been reported to 
contribute to EPCs involved angiogenesis [279]. It is reasonable to propose that 
CXCR2 may regulate the homing and angiogenesis in EPCs through PI3K/Akt 
and/or MAPK signaling pathways. 
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Interestingly, accumulating evidence has shown that RhoA is associated 
with the activities of both MAPK and PI3K/Akt signaling. It has been recently 
reported that RhoA is involved in the regulation of MAPK signaling activation in 
EPCs [216]. RhoA/ROCK pathway has been suggested be an upstream regulator 
of MAPK signaling molecules including ERK1/2, p38 MAPK, and JNK [211, 212, 
280]. Inhibition of ROCK decreased the activation of ERK1/2 and consequently 
attenuated the cell migration and proliferation in glioblastoma cells [214]. Recently, 
Zoledronate, which is used to treat hypercalcemia in clinic, has been shown to 
attenuate the angiogenesis in EPCs through inhibiting the activation of RhoA and 
MAPK pathway [216]. Meanwhile, RhoA also regulates the activity of PI3K/Akt 
signaling in a variety of cell lines. For instance, activated by RhoA, PI3K/Akt/MAPK 
signaling leads to upregulated production of hepatic growth factor in macrophage 
[281]. In addition, C3 exoenzyme, an inhibitor of RhoA, inhibited the activation of 
Akt in endothelial cells [282], indicating that RhoA activates Akt in endothelial cells. 
These findings provide the possibility that RhoA/ROCK pathway may be also 
involved in regulating MAPK and PI3K/Akt signaling in EPCs. 
RhoA activity is regulated by a variety of upstream signaling molecules. It 
has been reported that MIP-2, which is one of the murine CXCR2 ligands, activated 
RhoA in murine endothelial cells. Moreover, inhibition of RhoA signaling through 
ROCK inhibitor or siRNA targeting RhoA has significantly decreased endothelial 
cell migration during MIP-2/CXCR2 mediated angiogenesis [283]. Furthermore, 
CXCL8 has also been shown to be responsible for the actin cytoskeleton 
rearrangement for assembly of stress fibers and membrane ruffling through Rac1 
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and RhoA mediated signaling in HUVECs to promote the cell migration. In addition, 
dominant negative RhoA and constitutively active RhoA mutations were able to 
attenuated and facilitate CXCL8 mediated endothelial cell migration respectively, 
indicating the regulatory capacity of RhoA in this process [284]. It has been 
demonstrated that LIX, and MIP-2 and their cognate receptor CXCR2 are actively 
involved in ischemia induced angiogenesis, and blockade of CXCR2 diminished 
this process. Importantly, significant activation of RhoA has also been observed 
during this CXCR2 mediated angiogenesis [285]. All these findings have 
highlighted the importance of RhoA in CXCR2 signaling pathway. 
Taken together, it is reasonable to hypothesize that CXCR2 regulates EPC 
migration and angiogenesis in a RhoA/ROCK, PI3K/Akt, and MAPK dependent 
manner. 
3.2.2. Results 
3.2.2.1. MIP-2 treatment results in activation of RhoA in EPCs 
It is known that cell motility requires cells to experience alternating phases 
of protrusion and contraction. During migration, cells attach and adhere to the 
substrate such as ECM, and the adhesion provides the force for the cell body 
contraction and tail retraction. RhoA regulated stress fiber plays critical roles in 
these processes [286, 287], such as promoting cell adhesion and migration [288]. 
In my data, I have demonstrated that MIP-2 induced the migration of EPCs (Figure 
3.1.8). Moreover, it has been reported that MIP-2 was able to activate RhoA in 
endothelial cells to contribute to neovascularization [283, 285]. However, whether 
RhoA is involved in MIP-2 mediated migration in EPCs has not been studied. I 
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hypothesize that MIP-2 may activate RhoA through CXCR2 in EPCs to modulate 
EPCs functions. RhoA activation assay was used to test this hypothesis. In this 
assay, EPCs were incubated with MIP-2 for 0, 1, 3, and 6 min and were lysed. 
Then, the same amount of cleared cell lysates (400μg) from each group was used 
for GST-Rhotekin pulldown assay, and 5% of total cell lysate in each group was 
used as input. The amount of active RhoA present in the cells was determined by 
western blotting.  Figure 3.2.1 demonstrated that RhoA was activated in EPCs by 
MIP-2 (100ng/ml). The data showed that RhoA was activated 6 min after the MIP-
2 was administrated. This data demonstrated that RhoA could be activated by MIP-
2/CXCR2 signaling pathway in EPCs. 
 
 
                      
Figure 3.2.1. MIP-2 activated RhoA in EPCs. 
Upper panel shows that RhoA was activated by MIP-2 (100ng/ml) after 6 min of 
stimulation in EPCs. Lower panel shows the input (5% of cell lysate used for 
pulldown assay), which was used as loading control.  
 
3.2.2.2. PDZ-mediated interaction is involved in the activation of RhoA  
From the previous data, I have demonstrated that MIP-2/CXCR2 mediated 
EPCs migration, which could be attenuated by interrupting CXCR2 PDZ motif 
mediated interaction within the cells (Figure 3.1.8). Meanwhile, I have also shown 
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that RhoA, which provides forces for cell body contraction and tail retraction during 
cell migration [286, 287], was also activated by MIP-2 treatment (Figure 3.2.1). 
While whether the CXCR2 PDZ motif-mediated interaction is involved in MIP-2 
induced RhoA activation has not been investigated. RhoA and its major effector, 
ROCK, regulate actin reorganization to promote the assembly of focal adhesions 
and formation of actin stress fibers [289, 290]. I hypothesize that CXCR2 PDZ motif 
mediated interaction may play a role during the MIP-2 induced activation of RhoA. 
In order to test my hypothesis, I pre-incubated EPCs with ROCK inhibitor Y27632 
for 1 hour or delivered CXCR2 C-terminus peptide or ChariotTM reagent alone into 
EPCs before MIP-2 stimulation. Then cells were stimulated with MIP-2 (100ng/ml) 
for 0, 6, 12 min respectively. After that, immunofluorescence staining was 
performed to detect the actin formed stress fibers in each group. Figure 3.2.2 
showed that stress fibers could be observed in the control group (left column), in 
which EPCs were delivered with ChariotTM reagent alone, 6min after MIP-2 
stimulation. No stress fiber was observed in the Y27632 pre-incubated group (right 
column). However, compared to the control group, the formation of stress fibers in 
EPCs was delayed (observed 12min after MIP-2 treatment) and attenuated when 
the CXCR2 C-terminus peptide was delivered into EPCs as shown in the figure 
(middle column), indicating that CXCR2 PDZ motif-mediated interaction in EPCs 
is involved in activation of RhoA. 
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Figure 3.2.2. Disrupting CXCR2 PDZ motif-mediated interaction attenuated the 
activation of RhoA. 
RhoA activation in EPCs was reflected by stress fiber formation after MIP-2 
stimulation. Left column: Stress fibers were formed 6min after MIP-2 (100ng/ml) 
treatment in EPCs delivered with ChariotTM reagent alone. Middle column: In EPCs 
delivered with CXCR2 C-terminus PDZ peptide, the stress fibers were formed 
12min after MIP-2 (100ng/ml) treatment in EPCs, which was delayed compared to 
that in control group. In addition, the strength of the signal was weak compared to 
that in control group. Right column: The MIP-2 induced formation of stress fibers 
were barely observed in EPCs pre-incubated with ROCK inhibitor Y27632. 
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3.2.2.3. RhoA is involved in the MIP-2/CXCR2 signaling pathway  
It has been reported that CXCR2 signaling activates the MAPK signaling 
and PI3K/Akt signaling to regulate a variety of EPC functions including, 
mobilization, migration, and proliferation [43, 280]. Meanwhile, RhoA/ROCK has 
also been reported to regulate PI3K/Akt and MAPK signaling in endothelial cells 
and EPCs [283, 215]. Moreover, a clinical used drug to treat hypercalcemia, 
Zoledronate, has been reported to attenuate the angiogenic potential of EPCs by 
inhibiting the activities of RhoA and MAPK signaling [215]. My data has shown that 
MIP-2/CXCR2 signaling activated RhoA to form stress fiber, which is important in 
EPC migration and angiogenesis, and this activation was attenuated by disrupting 
CXCR2 PDZ motif mediated interaction in EPCs. It is possible that MAPK signaling 
or PI3K/Akt signaling may be involved in the MIP-2 induced EPC migration and 
disrupting PDZ mediated interactions would affect the activation of these signaling. 
In order to test this hypothesis, EPCs were starved and pre-incubated with Y27632, 
or delivered with WT CXCR2 C-terminus peptide or ChariotTM reagent alone before 
MIP-2 stimulation. Then cells were treated with MIP-2 (100ng/ml) for 0, 1, 3, 6, and 
12min respectively. After that the activation status of JNK, p38, ERK1/2, and Akt 
has been detected and compared among different groups as shown in Figure 3.3. 
The data shows that MIP-2 induced the phosphorylation of p38 (Figure 3.2.3.A), 
ERK1/2 (Figure 3.2.3.B), and Akt (Figure 3.2.3. C and D) in EPCs, but not JNK 
(data not shown), indicating that these molecules could be activated by CXCR2 
signaling. In addition, introducing WT CXCR2 C-terminus peptide into the EPCs to 
compete the PDZ mediated interactions attenuated the phosphorylation of those 
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molecules, indicating that CXCR2 PDZ motif-mediate interactions plays important 
role in CXCR2 mediated MAPK and PI3K/Akt activation. Moreover, Y27632 pre-
incubation has also inhibited the activation of those CXCR2 activated signaling 
molecules, which suggests that RhoA/ROCK is also involved in CXCR2 mediated 
MAPK and PI3K/Akt signaling transduction. 
 
 
 
Figure 3.2.3. RhoA/ROCK and PDZ-mediated interaction is involved in CXCR2 
induced activation of p38, ERK1/2, and Akt. 
EPCs were pre-incubated with Y27632, or delivered with WT CXCR2 C-terminus 
peptide or ChariotTM reagent alone before followed by starvation and MIP-2 
stimulation for 0, 1, 3, 6, and 12min. The data has shown that MIP-2 activated p38 
(A, upper panel), ERK1/2 (B, upper panel), and Akt (C and D, upper panel) in EPCs 
after 3 min incubation (upper panel), while the activation of p38 was not observed 
in WT CXCR2 C-terminus peptide delivered EPCs (A-D, middle panel) and Y27632 
pre-incubated EPCs (A-D, lower panel).  
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3.2.3. Discussion 
The importance of EPC in postnatal vascularization indicates its therapeutic 
potential. EPCs are involved in a variety of blood formation related disorders. Their 
instructive function (secret pro-angiogenic factors) and constructive function 
(incorporation and differentiation) are dysfunctional in cardiovascular diseases and 
diabetes which require blood vessel formation [9, 10, 72, 77, 78]. On the other 
hand, in the malignancies, EPCs contribute to tumor growth and progression 
through promoting angiogenesis [59-61]. So it is necessary to understand the 
underlying mechanism that regulates EPCs functions in these disorders. This 
study has shown that interrupting PDZ mediated interaction in EPCs attenuated 
the cell adhesion (Figure 3.1.7), migration (Figure 3.1.8), and angiogenesis (Figure 
3.1.11). These studies have suggested the potential therapeutic value of CXCR2 
PDZ motif-mediated interaction within EPCs. However, the underlying mechanism 
of how this PDZ-mediated interaction affect the cellular function has not been fully 
studied. Results from this study showed that RhoA, which is responsible for the 
formation of stress fibers and focal adhesions that play important roles in cell 
migration, was activated through MIP-2/CXCR2 axis (Figure 3.2.1). I have further 
demonstrated that interrupting PDZ mediated interaction in EPCs attenuated the 
MIP-2 induced stress fiber formation (Figure 3.2.2). Moreover, disrupting PDZ 
mediated interactions in EPCs have also attenuated the MIP-2 induced 
phosphorylation of p38 MAPK, ERK1/2, and Akt. In addition, similar results were 
observed when RhoA/ROCK signaling was inhibited in the cells (Figure 3.2.3). 
These results suggested that RhoA/ROCK and MAPK as well as PI3K/Akt may 
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contribute to the MIP-2 mediated chemotaxis of EPCs and PDZ mediated 
interactions may play a role in regulating the signaling transduction. This study has 
provided a potential signaling transduction pathway in regulating EPCs function. 
However, the exact role of each signaling molecules remains mysterious, which 
directs future studies toward the investigation of their functions during this process. 
It is worthy to determine the signaling cascades or network that are involved in this 
regulation process which could be helpful in identifying specific and efficient 
therapeutic target. 
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CHAPTER 4 CONCLUSION AND FUTURE DIRECTION 
4.1. Conclusion 
Derived from bone marrow, EPCs contribute to the adult vascularization 
through secreting pro-angiogenic factors and incorporating into angiogenic sites to 
differentiate into mature endothelial cells [4, 18]. The functions of EPC reflect its 
importance in physiological and pathological conditions. Mobilized by a variety of 
factors, EPCs will home to the sites of ischemia or vascular injury to promote the 
blood vessel formation [49-51]. Thus, a comprehensive understanding of the 
biology of EPC and the underlying mechanisms that regulate its homing and 
angiogenic activities could be helpful to identify potentially disease specific 
molecular targets in the cells for developing improved therapies. 
My research has demonstrated that the PDZ motif of CXCR2 plays 
important roles in EPC motility and angiogenic activity in vivo and in vitro. 
Disrupting the CXCR2 PDZ motif-mediated interactions in EPCs attenuated 
neovascularization, incorporation into endothelial network, and migration. 
Moreover, based on our previous finding of PDZ based CXCR2 involved 
macromolecular complex in neutrophil and pancreatic cancer cells [50, 96], the 
biochemical study of my research has suggested a CXCR2-NHERF1-PLCβ3 
complex in EPCs. In addition, I have also studied the possible mechanism that 
CXCR2 PDZ-mediated interaction affects EPC functions. I have found that the 
chemotaxis stimulus of EPCs activated RhoA in the EPCs and disrupting the 
CXCR2 PDZ-mediated protein-protein interactions attenuated the activation of 
RhoA as well as downstream signaling molecules including p38 MAPK, ERK1/2, 
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and Akt. The findings suggest the involvement of these signaling molecules in the 
CXCR2 mediated EPC cellular activities and also indicates their activations can be 
regulated by CXCR2 PDZ mediated interaction. My study, for the first time, 
demonstrated the importance of CXCR2 PDZ motif-mediated interaction in EPC 
biology and provided the potential involved signaling pathways. These findings 
contribute to our understanding of EPC biology and may be valuable in 
identification of novel therapeutic targets. My dissertation study provides the 
possibility that targeting the CXCR2 PDZ motif-mediated macromolecular complex 
is an effective approach to regulate the EPC dependent angiogenesis in different 
diseases. 
4.2. Future direction  
4.2.1. The role of MAPK signaling and PI3K/Akt signaling pathways in 
cellular functions have been intensively investigated.  
The MAPK signaling is composed of p38 MAPK pathway, MEK/ERK 
pathway, and JNK pathway [220-222]. It is well documented that p38 MAPK, 
ERK1/2, and Akt are involved in cell migration [216, 278] and angiogenesis [279, 
291-293]. Although I have shown in my results that disrupting CXCR2 PDZ motif-
mediated interaction attenuated the activation of p38 MAPK, ERK1/2, and Akt 
under the stimulation of MIP-2 in EPCs, it is still not known their exact role of them 
during MIP-2 induced EPC cellular activities. In order to have a more 
comprehensive understanding of the mechanisms that PDZ mediated interaction 
regulates EPC homing and angiogenesis, inhibitory studies will be performed. 
I speculate that the contribution of three signaling pathways in EPC 
functions are not equal. To test my hypothesis, I will block p38 MAPK (using 
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SB203580), ERK1/2 (U0126), or Akt (MK2206) signaling pathways in EPCs 
separately and perform EPC migration assay, adhesion assay, and in vitro tube 
formation assay under the stimulation of MIP-2. EPCs without inhibitor treatment 
will be used as negative control. I will observe the effects of different inhibitors on 
EPCs adhesion, migration, and in vitro angiogenesis to study how the three 
signaling pathways are involved in each EPC function. 
In parallel, I will also knockdown the expression of p38 MAPK, ERK1/2, or 
Akt by transiently transfect commercial available siRNAs targeting each signaling 
molecule respectively in EPCs. EPCs incubated with transfection reagent alone 
will be used as negative control. After the silencing each of the signaling molecules, 
I will stimulate the EPCs with MIP-2 and perform adhesion, migration, and in vitro 
tube formation assays. The effect of each pathway inhibition on each EPC function 
will be recorded and compared to study how the three signaling pathways are 
involved in each EPC function. 
4.2.2. Further study the PDZ mediated interaction on RhoA activation. 
As a member of small GTPase, the activity of RhoA is regulated by 
nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). My 
dissertation results showed that RhoA activation was affected by CXCR2 PDZ 
motif-mediated interactions (Figure 3.2.2). However, how did the PDZ-based 
interaction influence RhoA activation is still unclear. Our previous findings in 
neutrophil and pancreatic cancer cells [50, 96] have suggested the presence of 
PDZ-mediated CXCR2 involved complex in the cells to promote efficient and 
specific signaling transduction. Thus, I hypothesize that CXCR2 may form a protein 
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complex through its PDZ motif-mediated interaction with GEF to facilitate RhoA 
activation and disrupting this PDZ-mediated interaction would attenuate the 
activation of RhoA.  
I will perform immunoprecipitation followed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) to detect CXCR2 bound proteins 
mediated by PDZ-based interaction. To do this, I will clone full length CXCR2 or 
CXCR2 without PDZ motif with 3HA tagged at N-terminus into pcDNA3.1 vector 
(pcDNA3.1-3HA-CXCR2-FL; pcDNA3.1-3HA-CXCR2-dTTL). After that, I will 
transfect EPCs with pcDNA3.1-3HA-CXCR2-FL, pcDNA3.1-3HA-CXCR2-dTTL, or 
pcDNA3.1 vector alone respectively and stimulate cells with MIP-2. Then cells from 
each group will be lysed and 3HA tagged CXCR2-FL or CXCR2-dTTL and their 
bound proteins will be immunoprecipitated by anti HA agarose. The precipitated 
proteins will then be eluted and separated in a SDS-PAGE gel and digested to 
produce peptide for the tandem mass spectrometry to identify the bound proteins. 
After that, identified proteins from EPC expressing CXCR2-FL, CXCR2-dTTL, and 
pcDNA3.1 empty vector will be compared to obtain unique proteins including GEFs 
only found in CXCR2-FL group. It is possible that the list of unique proteins may 
contain the potential adaptor protein or GEFs containing PDZ domain. 
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Bone marrow-derived endothelial progenitor cells (EPCs) participate in 
postnatal vascularization in response to growth factors, cytokines, and 
chemokines. Chemokine receptor CXCR2 and its cognate ligands are reported to 
mediate EPC recruitment and angiogenesis. CXCR2 possesses a consensus 
PSD-95/DlgA/ZO-1 (PDZ) motif at its carboxyl terminus. The PDZ motif has been 
reported to regulate cellular signaling and functions. Here we investigated the 
potential role of the PDZ motif in CXCR2-mediated EPC motility and angiogenesis. 
We have found that introducing exogenous CXCR2 C-terminus significantly 
attenuated in vitro EPC migration and angiogenic activities in response to CXCR2 
ligands, as well as in vivo EPC angiogenesis. Meanwhile, the activation of RhoA, 
p38, ERK1/2, and Akt has also been inhibited due to the exogenous CXCR2 C-
terminus. On the other hand, delivering CXCR2 C-terminus without PDZ motif into 
EPCs did not significantly affect the functions of EPCs. Moreover, biochemistry 
study suggested that NHERF1, a PDZ domain containing scaffolding protein, 
preferred to interact with CXCR2 and its downstream effector, PLC-β3 in EPCs. 
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Taken together, the data has demonstrated the role of CXCR2 PDZ motif-mediated 
macromolecular complex in EPC homing and angiogenesis and also indicated 
potentially involved signaling pathways. The findings suggested that targeting 
CXCR2 PDZ motif-mediated interactions in EPCs may be a novel therapeutic 
approach in EPC dependent angiogenesis related diseases. 
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